WO2014006227A1 - Simultaneous detection of cannibalism and senescence as prognostic marker for cancer - Google Patents
Simultaneous detection of cannibalism and senescence as prognostic marker for cancer Download PDFInfo
- Publication number
- WO2014006227A1 WO2014006227A1 PCT/EP2013/064408 EP2013064408W WO2014006227A1 WO 2014006227 A1 WO2014006227 A1 WO 2014006227A1 EP 2013064408 W EP2013064408 W EP 2013064408W WO 2014006227 A1 WO2014006227 A1 WO 2014006227A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cell
- cells
- expression
- cannibalism
- sirna
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 103
- 230000009758 senescence Effects 0.000 title claims abstract description 92
- 201000011510 cancer Diseases 0.000 title claims abstract description 65
- 238000001514 detection method Methods 0.000 title claims abstract description 53
- 239000003550 marker Substances 0.000 title claims description 14
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims abstract description 260
- 230000014509 gene expression Effects 0.000 claims abstract description 184
- 230000001413 cellular effect Effects 0.000 claims abstract description 152
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims abstract description 145
- 230000000694 effects Effects 0.000 claims abstract description 115
- 238000000034 method Methods 0.000 claims abstract description 100
- 102000001744 Purinergic P2Y2 Receptors Human genes 0.000 claims abstract description 49
- 108010029812 Purinergic P2Y2 Receptors Proteins 0.000 claims abstract description 49
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 25
- 210000004027 cell Anatomy 0.000 claims description 494
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 116
- 102000001708 Protein Isoforms Human genes 0.000 claims description 89
- 108010029485 Protein Isoforms Proteins 0.000 claims description 89
- 102100028045 P2Y purinoceptor 2 Human genes 0.000 claims description 59
- 108090000623 proteins and genes Proteins 0.000 claims description 57
- 150000001875 compounds Chemical class 0.000 claims description 56
- 101710096700 P2Y purinoceptor 2 Proteins 0.000 claims description 54
- 102000004169 proteins and genes Human genes 0.000 claims description 49
- 108020004459 Small interfering RNA Proteins 0.000 claims description 47
- 210000004881 tumor cell Anatomy 0.000 claims description 47
- 238000000338 in vitro Methods 0.000 claims description 30
- 230000002401 inhibitory effect Effects 0.000 claims description 22
- 238000004113 cell culture Methods 0.000 claims description 19
- 238000011394 anticancer treatment Methods 0.000 claims description 18
- 230000005764 inhibitory process Effects 0.000 claims description 18
- 208000026310 Breast neoplasm Diseases 0.000 claims description 17
- 230000007423 decrease Effects 0.000 claims description 16
- 238000004393 prognosis Methods 0.000 claims description 15
- 239000002679 microRNA Substances 0.000 claims description 14
- 108091070501 miRNA Proteins 0.000 claims description 13
- 108020004999 messenger RNA Proteins 0.000 claims description 11
- 210000001519 tissue Anatomy 0.000 claims description 11
- 230000028327 secretion Effects 0.000 claims description 10
- 206010009944 Colon cancer Diseases 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 9
- 201000001441 melanoma Diseases 0.000 claims description 8
- 102000005962 receptors Human genes 0.000 claims description 8
- 108020003175 receptors Proteins 0.000 claims description 8
- 206010023256 Juvenile melanoma benign Diseases 0.000 claims description 7
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 7
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 7
- 238000003364 immunohistochemistry Methods 0.000 claims description 5
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 claims description 4
- 206010073069 Hepatic cancer Diseases 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 4
- 201000002250 liver carcinoma Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 35
- 238000009099 neoadjuvant therapy Methods 0.000 abstract description 15
- 201000008274 breast adenocarcinoma Diseases 0.000 abstract description 14
- 230000008569 process Effects 0.000 abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 230000008715 entosis Effects 0.000 abstract description 12
- 238000001727 in vivo Methods 0.000 abstract description 10
- 201000010099 disease Diseases 0.000 abstract description 9
- 230000004044 response Effects 0.000 abstract description 9
- 230000002100 tumorsuppressive effect Effects 0.000 abstract description 6
- 238000003745 diagnosis Methods 0.000 abstract description 3
- 230000003990 molecular pathway Effects 0.000 abstract description 3
- 102100037601 P2X purinoceptor 4 Human genes 0.000 abstract 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 abstract 1
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 71
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 71
- 229960001456 adenosine triphosphate Drugs 0.000 description 71
- 238000002474 experimental method Methods 0.000 description 67
- 210000002950 fibroblast Anatomy 0.000 description 46
- 101100338491 Oryza sativa subsp. japonica HCT1 gene Proteins 0.000 description 32
- 101100495309 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CDH1 gene Proteins 0.000 description 32
- 238000003119 immunoblot Methods 0.000 description 26
- 230000002779 inactivation Effects 0.000 description 26
- 101150080074 TP53 gene Proteins 0.000 description 25
- 238000004624 confocal microscopy Methods 0.000 description 25
- IPJDHSYCSQAODE-UHFFFAOYSA-N 5-chloromethylfluorescein diacetate Chemical compound O1C(=O)C2=CC(CCl)=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 IPJDHSYCSQAODE-UHFFFAOYSA-N 0.000 description 24
- 239000003112 inhibitor Substances 0.000 description 22
- 230000003362 replicative effect Effects 0.000 description 22
- 238000003197 gene knockdown Methods 0.000 description 20
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 20
- 238000010186 staining Methods 0.000 description 20
- 239000011435 rock Substances 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 230000035882 stress Effects 0.000 description 19
- 238000001574 biopsy Methods 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 238000011002 quantification Methods 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 16
- 108060000903 Beta-catenin Proteins 0.000 description 15
- 102000015735 Beta-catenin Human genes 0.000 description 15
- 230000006698 induction Effects 0.000 description 15
- 210000004940 nucleus Anatomy 0.000 description 15
- 230000028617 response to DNA damage stimulus Effects 0.000 description 15
- CDEURGJCGCHYFH-DJLDLDEBSA-N 5-ethynyl-2'-deoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C#C)=C1 CDEURGJCGCHYFH-DJLDLDEBSA-N 0.000 description 14
- 238000001000 micrograph Methods 0.000 description 13
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 12
- 230000004913 activation Effects 0.000 description 12
- 239000002924 silencing RNA Substances 0.000 description 12
- 230000004083 survival effect Effects 0.000 description 12
- 230000006870 function Effects 0.000 description 11
- 210000002510 keratinocyte Anatomy 0.000 description 11
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 10
- 230000004900 autophagic degradation Effects 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 10
- 235000008777 kaempferol Nutrition 0.000 description 10
- 230000007246 mechanism Effects 0.000 description 10
- 230000001404 mediated effect Effects 0.000 description 10
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 9
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 9
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 9
- 238000010348 incorporation Methods 0.000 description 9
- 230000003287 optical effect Effects 0.000 description 9
- 201000009030 Carcinoma Diseases 0.000 description 8
- 108010009491 Lysosomal-Associated Membrane Protein 2 Proteins 0.000 description 8
- 102100038225 Lysosome-associated membrane glycoprotein 2 Human genes 0.000 description 8
- 208000009956 adenocarcinoma Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 8
- 230000010094 cellular senescence Effects 0.000 description 8
- 238000006731 degradation reaction Methods 0.000 description 8
- 238000011068 loading method Methods 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 230000005778 DNA damage Effects 0.000 description 7
- 231100000277 DNA damage Toxicity 0.000 description 7
- MIFGOLAMNLSLGH-QOKNQOGYSA-N Z-Val-Ala-Asp(OMe)-CH2F Chemical compound COC(=O)C[C@@H](C(=O)CF)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)OCC1=CC=CC=C1 MIFGOLAMNLSLGH-QOKNQOGYSA-N 0.000 description 7
- 239000012190 activator Substances 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- -1 antisense molecules Proteins 0.000 description 7
- 108010005774 beta-Galactosidase Proteins 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 7
- 230000000973 chemotherapeutic effect Effects 0.000 description 7
- 230000000295 complement effect Effects 0.000 description 7
- 231100000590 oncogenic Toxicity 0.000 description 7
- 230000002246 oncogenic effect Effects 0.000 description 7
- 230000002018 overexpression Effects 0.000 description 7
- 229940127255 pan-caspase inhibitor Drugs 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 102000007347 Apyrase Human genes 0.000 description 6
- 108010007730 Apyrase Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 6
- 102000005936 beta-Galactosidase Human genes 0.000 description 6
- 230000000453 cell autonomous effect Effects 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 6
- 230000009038 pharmacological inhibition Effects 0.000 description 6
- 238000012552 review Methods 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 208000005623 Carcinogenesis Diseases 0.000 description 5
- 102000003952 Caspase 3 Human genes 0.000 description 5
- 108090000397 Caspase 3 Proteins 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 230000004568 DNA-binding Effects 0.000 description 5
- 108010091356 Tumor Protein p73 Proteins 0.000 description 5
- 102000018252 Tumor Protein p73 Human genes 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 230000036952 cancer formation Effects 0.000 description 5
- 231100000504 carcinogenesis Toxicity 0.000 description 5
- 230000030833 cell death Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000001086 cytosolic effect Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000001493 electron microscopy Methods 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000002372 labelling Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 108090000524 Beclin-1 Proteins 0.000 description 4
- 102000004072 Beclin-1 Human genes 0.000 description 4
- 101800001318 Capsid protein VP4 Proteins 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 4
- 101000986836 Homo sapiens P2Y purinoceptor 2 Proteins 0.000 description 4
- 101000799057 Homo sapiens tRNA-specific adenosine deaminase 2 Proteins 0.000 description 4
- 206010061309 Neoplasm progression Diseases 0.000 description 4
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 4
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 4
- 108010080192 Purinergic Receptors Proteins 0.000 description 4
- 102100027609 Rho-related GTP-binding protein RhoD Human genes 0.000 description 4
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 4
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 102100027881 Tumor protein 63 Human genes 0.000 description 4
- 101710140697 Tumor protein 63 Proteins 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000021953 cytokinesis Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 230000002132 lysosomal effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 230000037230 mobility Effects 0.000 description 4
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 108020001580 protein domains Proteins 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 108010054624 red fluorescent protein Proteins 0.000 description 4
- 230000008943 replicative senescence Effects 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 102100034045 tRNA-specific adenosine deaminase 2 Human genes 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 238000010865 video microscopy Methods 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 208000031448 Genomic Instability Diseases 0.000 description 3
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102100026925 Myosin regulatory light chain 2, ventricular/cardiac muscle isoform Human genes 0.000 description 3
- 102100040853 PRKC apoptosis WT1 regulator protein Human genes 0.000 description 3
- 101710162991 PRKC apoptosis WT1 regulator protein Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 208000020584 Polyploidy Diseases 0.000 description 3
- 101150094745 Ptk2b gene Proteins 0.000 description 3
- 102000000033 Purinergic Receptors Human genes 0.000 description 3
- 101150016368 TAD1 gene Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 201000010989 colorectal carcinoma Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 108010065781 myosin light chain 2 Proteins 0.000 description 3
- 230000026969 oncogene-induced senescence Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- HAGVCKULCLQGRF-UHFFFAOYSA-N pifithrin Chemical compound [Br-].C1=CC(C)=CC=C1C(=O)CN1[C+](N)SC2=C1CCCC2 HAGVCKULCLQGRF-UHFFFAOYSA-N 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 3
- 239000002987 primer (paints) Substances 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000004960 subcellular localization Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- 239000000225 tumor suppressor protein Substances 0.000 description 3
- 230000005760 tumorsuppression Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- CDEURGJCGCHYFH-UHFFFAOYSA-N 5-ethynyl-1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1C(O)C(CO)OC1N1C(=O)NC(=O)C(C#C)=C1 CDEURGJCGCHYFH-UHFFFAOYSA-N 0.000 description 2
- 231100000582 ATP assay Toxicity 0.000 description 2
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 230000022963 DNA damage response, signal transduction by p53 class mediator Effects 0.000 description 2
- 101100189891 Dictyostelium discoideum pepd gene Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 101100084166 Drosophila melanogaster prd gene Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101100335612 Escherichia coli (strain K12) fucA gene Proteins 0.000 description 2
- 108010034791 Heterochromatin Proteins 0.000 description 2
- 102100034533 Histone H2AX Human genes 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 102000004310 Ion Channels Human genes 0.000 description 2
- 108090000862 Ion Channels Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 101150117895 LAMP2 gene Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Chemical compound OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 102400000096 Substance P Human genes 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 2
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 208000036878 aneuploidy Diseases 0.000 description 2
- 231100001075 aneuploidy Toxicity 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000029918 bioluminescence Effects 0.000 description 2
- 238000005415 bioluminescence Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008614 cellular interaction Effects 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000002380 cytological effect Effects 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000010749 gastric carcinoma Diseases 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 210000004458 heterochromatin Anatomy 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 150000002611 lead compounds Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 230000006610 nonapoptotic cell death Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 108700025694 p53 Genes Proteins 0.000 description 2
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 150000002972 pentoses Chemical class 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000012660 pharmacological inhibitor Substances 0.000 description 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
- 210000001850 polyploid cell Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000003439 radiotherapeutic effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002287 time-lapse microscopy Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 1
- QCUPYFTWJOZAOB-HWKANZROSA-N (e)-n-carbamoyl-2-ethylbut-2-enamide Chemical compound CC\C(=C/C)C(=O)NC(N)=O QCUPYFTWJOZAOB-HWKANZROSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 1
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108700020463 BRCA1 Proteins 0.000 description 1
- 102000036365 BRCA1 Human genes 0.000 description 1
- 101150072950 BRCA1 gene Proteins 0.000 description 1
- 102000052609 BRCA2 Human genes 0.000 description 1
- 108700020462 BRCA2 Proteins 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 101150008921 Brca2 gene Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 102000001045 Connexin 43 Human genes 0.000 description 1
- 108010069241 Connexin 43 Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101710087047 Cytoskeleton-associated protein 4 Proteins 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 208000006402 Ductal Carcinoma Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000018693 Focal Adhesion Kinase 2 Human genes 0.000 description 1
- 108010091820 Focal Adhesion Kinase 2 Proteins 0.000 description 1
- 102000034286 G proteins Human genes 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101710195517 Histone H2AX Proteins 0.000 description 1
- 101710103773 Histone H2B Proteins 0.000 description 1
- 102100021639 Histone H2B type 1-K Human genes 0.000 description 1
- 101000944380 Homo sapiens Cyclin-dependent kinase inhibitor 1 Proteins 0.000 description 1
- 101001067891 Homo sapiens Histone H2AX Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 241000254158 Lampyridae Species 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241000714177 Murine leukemia virus Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-DGPXGRDGSA-J Nc1ncnc2c1nc[n]2[C@@H](C1O)O[C@H](COP([O-])(OP([O-])(OP([O-])([O-])=O)=O)=O)C1O Chemical compound Nc1ncnc2c1nc[n]2[C@@H](C1O)O[C@H](COP([O-])(OP([O-])(OP([O-])([O-])=O)=O)=O)C1O ZKHQWZAMYRWXGA-DGPXGRDGSA-J 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101150045976 P2ry2 gene Proteins 0.000 description 1
- 102000015982 Pannexin Human genes 0.000 description 1
- 108050004251 Pannexin Proteins 0.000 description 1
- 102100032361 Pannexin-1 Human genes 0.000 description 1
- 101710165201 Pannexin-1 Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 101710121439 Proteinase-activated receptor 4 Proteins 0.000 description 1
- 102100023710 Proteinase-activated receptor 4 Human genes 0.000 description 1
- 102000002294 Purinergic P2X Receptors Human genes 0.000 description 1
- 108010000836 Purinergic P2X Receptors Proteins 0.000 description 1
- 102000002298 Purinergic P2Y Receptors Human genes 0.000 description 1
- 108010000818 Purinergic P2Y Receptors Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241001400211 Speleostelium caveatum Species 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000007980 Sørensen’s phosphate buffer Substances 0.000 description 1
- DSFVPALDDWRTFF-DIBLVGDCSA-N TNP-ATP Chemical compound O([C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O1)N2C=3N=CN=C(C=3N=C2)N)C21C([N+]([O-])=O)C=C([N+]([O-])=O)C=C2[N+]([O-])=O DSFVPALDDWRTFF-DIBLVGDCSA-N 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- GFFAYTMBCSSULP-ICIWVTHHSA-I [[[bis[[(2r,5r)-3,4-dihydroxy-5-(6-oxo-3h-purin-9-yl)oxolan-2-yl]methoxy]phosphoryloxy-oxidophosphoryl]oxy-oxidophosphoryl]oxy-oxidophosphoryl] phosphate Chemical compound C1=NC(C(N=CN2)=O)=C2N1[C@@H]1O[C@H](COP(=O)(OC[C@@H]2C(C(O)[C@@H](O2)N2C3=C(C(N=CN3)=O)N=C2)O)OP([O-])(=O)OP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)C(O)C1O GFFAYTMBCSSULP-ICIWVTHHSA-I 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- LNQVTSROQXJCDD-UHFFFAOYSA-N adenosine monophosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(CO)C(OP(O)(O)=O)C1O LNQVTSROQXJCDD-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002886 autophagic effect Effects 0.000 description 1
- 230000007320 autophagy mechanism Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- QTPILKSJIOLICA-UHFFFAOYSA-N bis[hydroxy(phosphonooxy)phosphoryl] hydrogen phosphate Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(O)=O QTPILKSJIOLICA-UHFFFAOYSA-N 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000034196 cell chemotaxis Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- ZYWFEOZQIUMEGL-UHFFFAOYSA-N chloroform;3-methylbutan-1-ol;phenol Chemical compound ClC(Cl)Cl.CC(C)CCO.OC1=CC=CC=C1 ZYWFEOZQIUMEGL-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- XWZDJOJCYUSIEY-UHFFFAOYSA-L disodium 5-[(4,6-dichloro-1,3,5-triazin-2-yl)amino]-4-hydroxy-3-phenyldiazenylnaphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].Oc1c(N=Nc2ccccc2)c(cc2cc(cc(Nc3nc(Cl)nc(Cl)n3)c12)S([O-])(=O)=O)S([O-])(=O)=O XWZDJOJCYUSIEY-UHFFFAOYSA-L 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 210000005175 epidermal keratinocyte Anatomy 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- BJDWURMSYDDCRX-UHFFFAOYSA-N ethoxycarbonyl ethyl carbonate;hydrate Chemical compound O.CCOC(=O)OC(=O)OCC BJDWURMSYDDCRX-UHFFFAOYSA-N 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 230000008295 exocytic mechanism Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 102000034345 heterotrimeric G proteins Human genes 0.000 description 1
- 108091006093 heterotrimeric G proteins Proteins 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000000579 hyperploidy effect Effects 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- GZZCYMXZJQCAJU-UHFFFAOYSA-N isoquinoline-1-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)N)=NC=CC2=C1 GZZCYMXZJQCAJU-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000006674 lysosomal degradation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108091029119 miR-34a stem-loop Proteins 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 238000011227 neoadjuvant chemotherapy Methods 0.000 description 1
- 230000011242 neutrophil chemotaxis Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 102000041788 p53 family Human genes 0.000 description 1
- 108091075611 p53 family Proteins 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 230000003567 photophosphorylation Effects 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000007859 posttranscriptional regulation of gene expression Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000000111 purinergic antagonist Substances 0.000 description 1
- 230000001696 purinergic effect Effects 0.000 description 1
- 229940121374 purinergic receptor antagonist Drugs 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000020129 regulation of cell death Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108091069025 single-strand RNA Proteins 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000028070 sporulation Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000003518 stress fiber Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000007755 survival signaling Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- VZPXDCIISFTYOM-UHFFFAOYSA-K trisodium;1-amino-4-[4-[[4-chloro-6-(3-sulfonatoanilino)-1,3,5-triazin-2-yl]amino]-3-sulfonatoanilino]-9,10-dioxoanthracene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S([O-])(=O)=O)C=C1NC(C=C1S([O-])(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S([O-])(=O)=O)=C1 VZPXDCIISFTYOM-UHFFFAOYSA-K 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Abstract
The present inventors show that cannibal cells can undergo senescence after entosis in vivo and that the tumor suppressive protein p53 act as a repressor of this phenomenon. They therefore propose new tools to study the molecular pathways involved in the cannibalism process, for example by measuring the expression levels of p53 or splice variants thereof (such as Δ133ΤΡ53, ΤΡ53β, ΤΡ53γ or Δ40ΤΡ53), the release of extracellular ATP or purinergic P2Y2 receptor activity. The present inventors also demonstrated that the detection of senescent cannibal cells in breast adenocarcinoma obtained from patients treated with neo-adjuvant therapy positively correlates with good patient's response to treatment. Altogether, these results provide the first evidence that detection of cellular cannibalism and senescence simultaneously in tumors helps for the diagnosis of disease outcomes and for the prediction of treatment efficiency against cancer diseases.
Description
SIMULTANEOUS DETECTION OF CANNIBALISM AND SENESCENCE AS PROGNOSTIC MARKER FOR CANCER
SUMMARY OF THE INVENTION The present inventors show that cannibal cells can undergo senescence after entosis in vivo and that the tumor suppressive protein p53 act as a repressor of this phenomenon. They therefore propose new tools to study the molecular pathways involved in the cannibalism process, for example by measuring the expression levels of p53 or splice variants thereof (such as Δ133ΤΡ53, ΤΡ53β, ΤΡ53γ or Δ40ΤΡ53), the release of extracellular ATP or purinergic P2Y2 receptor activity. The present inventors also demonstrated that the detection of senescent cannibal cells in breast adenocarcinoma obtained from patients treated with neo-adjuvant therapy positively correlates with good patient's response to treatment. Altogether, these results provide the first evidence that detection of cellular cannibalism and senescence simultaneously in tumors helps for the diagnosis of disease outcomes and for the prediction of treatment efficiency against cancer diseases.
BACKGROUND OF THE INVENTION
Cannibalism constitutes a consumption strategy used by micro- and higher organisms to adapt to environmental stresses and to survive. Gram positive species, Bacillus subtilis and Streptococcus pneumonia exert cannibalistic activities during the early stages of sporulation (Gonzalez-Pastor et al., Science 2003) or during natural genetic
transformation (Guiral et al, PNAS 2005). In contrast, the slime molde Dictyostelium caveatum represses its predatory abilities during its quasi-multicellular differentiation stage (Waddell and Duffy, The Journal of cell biology 1986). In Drosophila, studies on genetic mosaics that place cells in competition within tissues unrevealed that cannibalism is a genetically controlled process that may occur at the single cell level and actively participates to cell competition during tissue repair and tumor development (Li and Baker, Cell 2007). Although cellular cannibalism is poorly reported in physiological situations, cannibal cells have been frequently detected in various human tumor types such as melanoma, leukemia and cervical carcinoma, colon carcinoma, stomach carcinoma, liver carcinoma adenocarcinoma and in metastatic breast carcinoma (Overholtzer and Brugge, Nature reviews Molecular cell biology 2008).
On a one hand, cellular cannibalism was suggested to cause the destruction of cancer cells by other malignant cells by entosis. In contrast to other (apoptotic, necrotic or autophagic) cell death forms that are controlled in a cell-autonomous fashion, entosis (from the Greek word entos, which means inside, into, or within) requires the internalization of a live « target » cancer cell by a live « cannibal » cancer cell (Overholtzer and Brugge, Nature reviews Molecular cell biology 2008). An inverse correlation between entosis and metastasis appearance in human pancreatic adenocarcinoma was furthermore reported, suggesting that this atypical death process may represent an intrinsic tumor suppression mechanism (Cano et al, EMBO Mol Med. 2012).
On another hand, cellular cannibalism was shown to provoke the polyploidization of the engulfing cell by disrupting cytokinesis, and hence to promote oncogenesis indirectly,
by generating polyploid cells that tend to generate aneuploidy daughter cells (Krajcovic et al, Nat Cell Biol. 2011; Krajcovic and Overholtzer, Cancer Res. 2012).
As a consequence of (homotypic or heterotypic) interactions between cancer cells or between cancer cells and other (stromal or immune) cells, cannibalism could have - depending on the genetic status of cancer cells (target and cannibal cells) and on tumor microenvironment - variable consequences on tumor growth and disease outcomes.
Although the "cell-in-cell" cytological features have been widely reported in human tumors, the molecular and cellular bases of cellular cannibalism remain unknown.
In this context, the present inventors provide evidence that TP53 and, more specifically, Δ133ΤΡ53, acts as repressors of cellular cannibalism. Their results also unrevealed that cellular cannibalism is functionally connected to senescence, both in vitro (in cellular models of senescence) and in vivo (in human breast carcinoma), where they may influence the efficiency of a chemo therapeutic treatment.
FIGURE LEGENDS
Figure 1. Identification of TP53 as repressor of cellular cannibalism. (A) Schematic representation of experimental procedure used to evaluate the ability to tumor suppressive depletion to enhance cell in cell internalization. (B) Frequencies of cell-in-cell structures induced by depletion of tumor suppressive proteins in HCT116. After 48 hours of transfection indicated siRNA, colorectal HCT1 16 cells were stained with CMTMR and CMFDA cell trachers, mixed and cultured during 24 hours. Quantification of cell-in-cell structures induced by depletions of tumor suppressor proteins was realized by confocal microscopy. The
frequencies of cell-in-cell structures were determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, p<0.001). (C) Detection of cell-in-cell structures induced by depletion of TP53, as visualized by confocal microscopy. Inserts represent xz and yz optical sections and show that after p53 depletion, red CMTR labeled HCTl 16 cells are internalized by green CMFDA labeled HCTl 16 cells. Representative micrographs of xy (scale bar, 5μιη), xz (scale bar, 4μιη) and yz (scale bar, Ι μιη) optical sections are shown. Images are representative of at least four independent experiments. (D) Representative micrographs of cell-in-cell structures showing that after depletion of TP53 by two specific siRNAs, (red) CMTR labeled HCTl 16 cells internalized (red) CMTR labeled HCTl 16 cells (noted R(R)) or (green) CMFDA labeled HCTl 16 cells (noted R(G)), and (green) CMFDA labeled HCTl 16 cells engulfed (red) CMTR labeled HCTl 16 cells (noted G(R)) or (green) CMFDA labeled HCTl 16 cells (noted G(G)) (scale, 5μιη). (E) Frequencies of cell-in-cell structures showing R(R), R(G), G(R) or G(G) cell internalization detected after depletion of TP53 by two distinct siRNAs (as compare to control). The frequencies of cell-in-cell structures were determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, p<0.001). (F) Cell-in-cell structures induced by 10 μΜ PFT-α, TP53 knockdown, or TP53 knockout in HCTl 16. Cell-in-cell structures were identified by b-catenin (white), CMFDA (green) and CMTMR (red) staining of internalizing HCTl 16 cells. Images are representative of at least four independent experiments (scale bar in a, 5μιη and scale bar in b, Ι μιη). (G) Frequencies of cell-in-cell structures induced by 10 μΜ PFT- α, TP53 knockdown, or TP53 knockout in HCTl 16 in presence or in absence of 20 μΜ of ROCK inhibitor (Y27632) or 100 μΜ of pan-caspase inhibitor (zVAD). The frequencies of cell- in-cell structures were determined for at least 300 cells in 3 independent experiments (mean+/- s.e.m, p<0.001). (H) Detection of cell-in-cell structures in TP53 depleted human diploid fibroblasts strain WI38, as visualized by confocal microscopy. Inserts represent xz and yz optical sections and show that after TP53 depletion, red CMTR labeled primary WI38 cells are internalized by green CMFDA labeled HCTl 16 cells. Representative micrographs of xy (scale
bar, 5μηι), xz (scale bar, 4μηι) and yz (scale bar, Ι μηι) optical sections are shown. Images are representative of at least four independent experiments. (I) Frequencies of cell-in-cell structures induced by depletion of TP53 in human diploid fibroblasts strain WI38. The frequencies of cell- in-cell structures were determined for at least 300 cells in 3 independent experiments (mean+/- s.e.m, p<0.001).
Figure 2. Δ133ΤΡ53 isoform is also a repressor of cellular cannibalism. (A-D) Effects of TP53 mutants and TP53 isoforms on cell-in-cell internalization in Tp53' HCT116 cells. Schematic representation of TP53 mutants and isoforms used in this study (A). Expression of TP53 mutants in Tp53' HCT116 cells was validated by Western blot. Immunoblot shown is representative of 3 independent experiments (B). Representative micrographs of Tp53' transfected with plasmids expressing WT (TP53WT), nuclear (TP53NES~), cytoplasmic (TP53NLS~) or mutated TP53 (TP53R175H and TPSS 27311) are shown (C). Quantification of cell-in-cell structures of Tp53' cells transiently transfected with TP53 mutants is shown (mean+/- s.e.m, n=3, p<0.001) (D). Micrographs of Tp53' cells transfected with plasmids expressing wild type TP53, ΤΡ53β, ΤΡ53γ, Δ40ΤΡ53 or Δ133ΤΡ53 isoforms are shown (E). Quantification of cell-in- cell structures of Tp53' cells transiently transfected with wild type TP53 or TP53 isoforms (TP53, ΤΡ53β, ΤΡ53γ, Δ40ΤΡ53 or Δ133ΤΡ53) is shown (mean+/- s.e.m, n=3, p<0.001) (F). (G- I) Effects of Δ133ΤΡ53 depletion on cell-in-cell internalization in HCT116 cells. Depletion of Δ133ΤΡ53 in HCT1 16 cells was validated by Western blot (n=3)(G). Detection of cell-in-cell structures induced by depletion of Δ133ΤΡ53 by confocal microscopy. Representative micrographs of xy (scale bar, 5μιη), is shown. Image is representative of at least four independent experiments (K). Frequencies of cell-in-cell structures induced by depletion of Δ133ΤΡ53 in human diploid fibroblasts strain WI38. The frequencies of cell-in-cell structures were determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, p<0.001)
(L). Effects of TP53 or Δ133ΤΡ53 knockdown and TP53 knock out on cell engulfment. Quantification of cell-in-cell structures obtained after culture of TP53- or Δ133ΤΡ53- depleted HCT116 cells (red) with CMFDA labeled HCT1 16 target cells is shown (mean+/- s.e.m, n=3, p<0.001) (M).
Figure 3. Extracellular ATP and purinergic receptor P2Y2 participate in cellular cannibalism induced by TP53 or Δ133ΤΡ53 depletion. (A) Release of ATP during coculture of Tp53' (black circle) or Tp53+/+ (white circle) HCT1 16 cells was determined at different time points by ATP- dependent bioluminescence in 3 independent experiments. One representative experiment is shown (mean ± SEM of triplicates; *P < 0.01). (B) Effect of apyrase on cellular cannibalism. Cocultures of TP53 or Δ133ΤΡ53 depleted HCT116 cells in presence of different concentrations of apyrase were performed. Then, detection of cell-in-cell structures was performed by confocal microscopy (mean+/- s.e.m, n=3, p<0.001). (C,D) Effects of extracellular ATP and UTP on cellular cannibalism. Detection of cell-in-cell structures induced after the supplementation of ATP or UTP on culture of CMFDA and CMTMR labeled HCT1 16 cells. Representative micrographs are shown (scale bar, 5μιη). Images are representative of at least 3 independent experiments (C). Frequencies of cell-in-cell structures induced by ATP or UTP supplementations in HCT116 in presence or in absence of 20 μΜ of ROCK inhibitor (Y27632) or of 100 μΜ pan-caspase inhibitor (zVAD). The frequencies of cell-in-cell structures were determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, p<0.001) (D). (E- F) Overexpression of P2Y2 after TP53 or Δ133ΤΡ53 depletions on colorectal carcinoma HCT116 cells. Expression was determined by immunoblot. Representative immunoblots of 3 independent experiments are shown. (G,H) Effects of P2Y2 depletion on cellular cannibalism observed after TP53 or Δ133ΤΡ53 depletions. As previously described, HCT116 (G) or PANC813 (H) cells that are depleted for P2Y2 and/or inactivated for TP53 or Δ133ΤΡ53 were
stained, mixed and cultured during 24 hours in presence or in absence of 20 μΜ of Y27632 or 100 μΜ of zVAD. The frequencies of cell-in-cell structures were determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, *p<0.001). (I- J) P2Y2 expression on human primary fibroblasts after TP53 or Δ133ΤΡ53 depletions. Expression was determined by immunoblot. Representative immunoblots of 3 independent experiments are shown. (K) Effects of pharmacological inhibition of P2Y2 on cellular cannibalism induced by Δ133ΤΡ53 depletion. Human primary fibroblasts that are depleted for Δ133ΤΡ53 were stained, mixed and cultured during 24 hours in presence or in absence of the 20 μΜ of P2Y2 inhibitor Kaempferol. The frequencies of cell-in-cell structures were determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, p<0.001).
Figure 4. Cellular cannibalism leads to senescence. (A,B) Effects of cellular cannibalism on cell proliferation. After cell sorting, cell proliferation of TP53 or Δ133ΤΡ53 knocked down and TP53 knocked out single or cannibal cells were performed during 6 days. (C-H) Effects of cellular cannibalism on senescence induction. Cannibal cells mediated by TP53 knockout or Δ133ΤΡ53 knockdown were examined in EdU incorporation assay (C,D), in DNA damage response (E,F) and in SA-P-Gal assay (G,H). (C) Determination of EdU incorporation on cannibal cells induced by Δ133ΤΡ53 knockdown, or TP53 knockout. Cell-in-cell structures were identified by β-catenin (red) and Hoechst 33342 (blue) staining of internalizing HCT1 16 cells. EdU positive cells are green. Images are representative of at least three independent experiments (scale bar: 5μιη). (D) Determination of EdU incorporation in single and cannibal cells after TP53 or Δ133ΤΡ53 inactivation. The number of EdU positive single or cannibal cells per total number of cells examined (at least 300 per well) was recorded. (E) Detection of DNA damage response (DDR) foci in single and cannibal cells after TP53 or Δ133ΤΡ53 inactivation. DNA damage response (DDR) foci were identified by γ-Η2ΑΧ or p53BPl (white), CMFDA
(green), CMTMR (red) and Hoechst 33342 (blue) staining of internalizing HCT1 16 cells. Images are representative of at least three independent experiments (scale bar: 5μιη). (F) Quantification of DNA damage foci in single and cannibal cells after TP53 or Δ133ΤΡ53 inactivation. The percentage of γ-Η2ΑΧ+ cells or p53BPl+ cells were determined by confocal microscopy. Error bars represent means ± SEM (n = 3; *P < 0.01). Representative pictures of SA-β Gal staining of single and cannibal cells obtained after TP53 or Δ133ΤΡ53 inactivation. (H) Summary of SA-β Gal assay. The data are mean ± SEM (n = 3; *P < 0.01). (I) p21WAF1 expression during coculture of Tp53+/+ or TP53' cells. P21WAF1 expression was determined by immunoblot. Representative immunoblots of 3 independent experiments are shown. (J) Detection of p21WAF1 expression in cannibal cells after Δ133ΤΡ53 depletion. Expression of p21WAF1 was examined by confocal microscopy using antibodies against p21WAF1 (white) or β- catenin (red). Nuclei are stained with Hoechst 33342 (blue). Images are representative of at least three independent experiments (scale bar: 5μιη). (K) Quantification of p21WAF1 expression in single and cannibal cells after TP53 or Δ133ΤΡ53 inactivation. The percentage of D21WAF+ cells in cannibal cells was determined by confocal microscopy. Error bars represent means ± SEM (n = 3; *P < 0.01). (L) Expression of p21WAF1 on HCT1 16 Tp53' after knockdown of p21WAF1. P21WAF1 expression was determined by immunoblot. Representative immunoblots of 3 independent experiments are shown. (M) Effects of p21WAF1 depletion on SA-β Gal activity of cannibal cells. The number of SA-β Gal positive single or cannibal cells per total number of cells examined (at least 300 per well) was recorded. Error bars represent means ± SEM (n = 3; *P < 0.01). (N) Effects of p21WAF1 knockdown on SA-β Gal activity of cannibal cells obtained after TP53 or Δ133ΤΡ53 inactivation. Quantification of SA-β Gal positive cells were realized as described above (n = 3; means ± SEM; *P < 0.01). (O) Effects of p21WAF1 knockdown on cell- in-cell internalization detected after TP53 or Δ133ΤΡ53 inactivation. Cell-in-cell structures were identified by β-catenin (white), CMFDA (green) and CMTMR (red) staining of transfected
HCT116 cells. The frequencies of cell-in-cell structures were determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, p<0.001).
Figure 5. Senescent cells exert cannibalistic activity.(A) Detection of P2Y2 overexpression during oncogenic induced senescence. Expression of P2Y2, p21WAF1, pl6INK4b and Rb during retroviral transduction of oncogenic Rasv12 in human primary fibroblasts (WI38) were determined by immunoblot. Representative immunoblot of three independent experiments was shown. GAPDH was used as loading control. (B) Detection of cell-in-cell structures during coculture of human primary fibroblasts or RasV12 expressing human primary fibroblasts with human primary fibroblasts, with RasV12 expressing human primary fibroblasts or with colorectal HCT116 cells. Cell-in-cell structures were analyzed by confocal microscopy. Inserts represent xz and yz optical sections and show that Rasv12 expressing fibroblasts internalized neighboring cells (human primary fibroblasts or HCT116 cells-. Representative micrographs of xy (scale bar, 5μιη), xz (scale bar, 4μιη) and yz (scale bar, Ι μιη) optical sections are shown. Images are representative of at least three independent experiments. (C) Frequencies of cell-in- cell structures induced after transduction of oncogenic Rasv12 in human diploid fibroblasts (WI38). The frequencies of cell-in-cell structures were determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, p<0.001). (D) Detection of P2Y2 overexpression during replicative stress induced senescence. Expression of P2Y2, p21WAF1, pl6INK4b and Rb during replicative senescence in human primary fibroblasts (WI38) were determined by immunoblot. Representative immunoblot of three independent experiments was shown. GAPDH was used as loading control. (E) Frequencies of cell-in-cell structures induced during replicative stress in human diploid fibroblasts (WI38). The frequencies of cell-in-cell structures were determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, p<0.001). (F) Effects of pharmacological inhibition of P2Y2 on cellular cannibalism detected during
replicative induced senescence. Coculture of replicative stress induced senescent human fibroblasts with human primary fibroblast or colorectal HCT1 16 cells were realized during 24 hours in presence or in absence of 33 μΜ of Kaempferol. Then, frequencies of cell-in-cell structures induced during replicative stress in human diploid fibroblasts (WI38) were determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, p<0.001). (G) Detection of P2Y2 overexpression during replicative stress induced senescence on human primary keratinocyte. Expression of P2Y2, pl6INK4b and Rb during replicative senescence in human primary keratinocytes (HEKn) were determined by immunoblot. Representative immunoblot of three independent experiments was shown. GAPDH was used as loading control. (H) Detection of cell-in-cell structures during culture of human primary keratinocytes after 3 passages (P3), 4 passages (P4) or 5 passages (P5). A previously described, cell-in-cell structures were analyzed by confocal microscopy. Inserts represent xz and yz optical sections and show that replicative stress induced senescent fibroblasts internalized neighboring cells (human primary fibroblasts or HCT1 16 cells). Representative micrographs of xy (scale bar, 5μιη), xz (scale bar, 4μιη) and yz (scale bar, Ι μιη) optical sections are shown. Images are representative of at least three independent experiments. (I) Effects of pharmacological P2Y2 inhibitor of P2Y2 on cellular cannibalism detected during replicative induced senescence. Coculture of replicative stress induced senescent human fibroblasts with human primary fibroblast or colorectal HCT116 cells were realized during 24 hours in presence or in absence of 33 μΜ of Kaempferol, 20 μΜ of Y27632 and 100 μΜ of ZVAD. Then, frequencies of cell-in- cell structures induced during replicative stress in human primary keratinocytes (HeKn) were determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, p<0.001).
Figure 6. Detection of cell-in-cell structures during culture of cancer cell lines and validation of tumor suppressor knockdowns. (A) Frequencies of cell-in-cell structures detected during culture of different cell lines as previously described. HCT116, HT29, H1299, PANC813, H1975, H1650, A549, HCC1937, SQ20B, HeLA and U20S cells were stained with CMTMR or CMFDA cell trackers, mixed and cultured during 24 hours. Quantification of cell-in-cell structures was realized by confocal microscopy. The frequencies of cell-in-cell structures were determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, p<0.001). (B-Q) Validation of tumor suppressor knockdowns after transfection of two siRNA for Par-4 (B), BRCA-2 (C), PTEN (D), ATR (E), FOXO-1 (F), BRCA-1 (G), Beclin-1 (H), ATM (I), FOXO-4 (J), FOXO-3 (K), Rb (L), TP63 (M), TP73 (N), LKB1 (O), pl5I Kb (P) and TP53 (Q) was performed. Expression of indicated tumor suppressive proteins was determined by immunoblot. Representative immunoblots of three independent experiments are shown. GAPDH was used as loading control.
Figure 7. Effects of TP53 inactivation on cellular cannibalism. (A) Detection of cell-in-cell structures induced by depletion of TP53, as visualized by confocal microscopy. Inserts represent xz and yz optical sections and show that after p53 depletion, red CMTR labeled HCT1 16 cells are internalized by green CMFDA labeled HCT1 16 cells. Images are representative of at least four independent experiments. (B) Detection of cell-in-cell structures induced by depletion of TP53 by light microscopy. (C) Time-lapse imaging of cellular cannibalism detected after depletion of TP53 on HCTT116 cells. After 48 hours of transfection with siRNA against TP53, cells were stained as previously described with CMFDA and CMTMR cell trackers and cocultured under time-lapse confocal videomicroscopy. Indicated numbers represent hours and minutes. Time-lapse videomicroscopy image sequences shown are representative of at least three independent experiments. (D) Absence of apoptotic cleavage of caspase-3 during depletion of TP53. After 48 hours of TP53 knockdown, cleavage of caspase-3 was analyzed by
immunoblot. Note that 100 mM of cis latin (CDDP) used as positive control revealed intense cleavage of caspase-3. GAPDH was used as loading control. Representative immunoblots of three independent experiments were shown. (E) Analyze of 20 independent Time-lapse videomicroscopy image sequences. Mitotic events and cellular cannibalism were detected and recorded during approximately fifteen hours. (F) Impact of TP53 inactivation on ROCK activity. ROCK activity was determined by detecting the phosphorylation of myosin light chain 2 on serine 19 (MLC2S19*). Lysates for 10 μΜ PFT-α treated-, TP53 knocked down, or TP53 knocked out HCT116 cells were analyzed for MLC2S19*, MLC2 or TP53 by immunoblot. GAPDH was used as loading control. Representative immunoblots of three independent experiments are shown. (G) Electron microscopy micrographies of cannibal cells. After 24 hours of culture, Tp53+/+ and Tp53' HCT116 cells are fixed and analyzed by electron microscopy. Representative electron microscopy micrographies of three independent experiments are shown. (H,I) Effects of TP53 depletion on TP53 expression and on MLC2S19*. HCT116 cells were transfected with specific siRNAs for TP53 during 48 hours and expression of TP53 (H) or MLCS19* (I) were determined by immunoblots. GAPDH was used as loading control. Representative immunoblots of three independent experiments are shown.
Figure 8. Depletion of Δ133ΤΡ53 triggers cellular cannibalism of PANC813 cells and of human primary fibroblasts. (A) Detection of cell-in-cell structures after depletion of Δ133ΤΡ53 in PANC813 cells. After 48 hours of transfection with two specific siRNAs for Δ133ΤΡ53, PANC813 cells were stained as previously described, with CMFDA and CMTMR cell trackers and cocultured during 24 hours. Then, cells were fixed and stained for β-catenin (white) and nuclei (blue). Detection of cell-in-cell structures induced by depletion of Δ133ΤΡ53, as visualized by confocal microscopy. Representative micrographs are shown. Images are representative of at least four independent experiments (scale bar, 5μιη). (B) Analysis of
Δ133ΤΡ53 depletion in human diploid fibroblasts. Expression of Δ133ΤΡ53 was GAPDH was used as loading control. Representative immunoblots of three independent experiments are shown.
Figure 9. Internalized cells are degraded by cannibal cells. (A) Detection of subcellular localization of lysosomal marker LAMP2 in cannibal cells obtained after PFT- α treatment, TP53 knockdown, or TP53 knockout. Subcellular localization of LAMP2 on cannibal cells was examined by confocal microscopy by LAMP2 (white), CMFDA (green), CMTMR (red) and Hoechst 33342 (blue) staining of HCT116 (A) or PANC0813 (B) cells. (C) Quantification of LAMP2 recruitment to internalized cells. The frequencies of LAMP2 encircled nuclei were determined for at least 300 cells in 3 independent experiments (mean+/- s.e.m, p<0.001). (D) Detection of lysosomal compartment in cannibal cells obtained after coculture of Tp53' HCT1 16 cells. As in (A), Subcellular localization of lysosomal compartment on cannibal cells was examined by confocal microscopy by β-catenin (white), LAMP2 (green), Lysotracker (red) and Hoechst 33342 (blue) staining of Tp53~'~ HCT116 cells. (E) Detection of target cell degradation during cellular cannibalism. Isogenic Tp53' HCT116 cells that stably expressed green or red fluorescent proteins in their nuclei (GFP-histone H2B and RFP-histone H2B fusion proteins) were mixted and cocultured for 24 hours. After fixation, these cells were analyzed by confocal microscopy or by electron microscopy and revealed that internalized cells are degraded. (F) Detection of nuclear degradation of internalized cells during cellular cannibalism obtained after culture of isogenic Tp53 /_ HCT116 cells. Cannibal cells were examined by detecting EdU (green), a-tubulin (red), Hoechst 33342 (blue) stainings and phase contrast (grey) using confocal microscopy. Representative micrographs are shown. Images are representative of at least four independent experiments (scale bar, 5μιη). (G) Quantification of nuclear degradation of internalized cells during cellular cannibalism induced by TP53 and
Δ133ΤΡ53 inactivation. The frequency nuclear degradation of internalized cells was determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, p<0.001).
Figure 10. Identification and characterization of cannibal cells after cell sorting. Isogenic pairs of cancer cell lines (HCT116 Tp53+/ PANC813) that stably expressed green or red fluorescent proteins in their nuclei (GFP-histone H2B and RFP-histone H2B fusion proteins) were mixted, cocultured, optionally after depletion of Δ133ΤΡ53 to induce entosis, and seeded in microtiter plates (with one single structure per well) after cell sorting and analyzed by fluorescent microscopy. (A) Representative micrographs of cannibal cells obtained from HCT1 16 or PANC (Day 1 and Day7) are shown. (B) Time-lapse videomicroscopy image sequences shown are representative of at least three independent experiments obtained after Δ133ΤΡ53 depletion.
Figure 11. Extracellular ATP and purinergic receptor P2Y2 participate in cellular cannibalism. (A) Detection of cellular cannibalism after cis-platinium (CDDP) or γ-irradiation (IR) treatment. After 24 hours treatment with 10 μΜ CDDP or irradiation (IR) with 4 grays, half cell population of colon carcinoma HCT116 cells were stained with green CMFDA cell tracker or with red CMTMR cell tracker and analyzed for cellular cannibalism by confocal microscopy after 24 hours of coculture in presence or in absence of 20 μΜ of ROCK inhibitor (Y27632) or 100 μΜ of pan-caspase inhibitor (zVAD). The frequencies of cannibal cells were determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, *p<0.001). (B-D) Detection of ATP release after stimulation with senescent- induced stresses. Release of ATP on HCT1 16 cells treated with 10 μΜ CDDP (B) or 4 gray γ-irradiation (IR) (B) or depleted for p53 (C) or Δ133ρ53 (C) was determined 2 hours after the beginning of coculture using ATP-dependent bioluminescence in 3 independent experiments. (D) Effect of ROCK inhibitor on ATP release
detected after p53 inactivation. Release of ATP was detected as previously described in presence or in absence of 20 μΜ of Y27632 (mean+/- s.e.m, n=3, *p<0,001). (E) Effects of extracellular ATP and UTP on cellular cannibalism. Detection of cell-in-cell structures induced after the supplementation of ATP or UTP on culture of CMFDA and CMTMR labeled HCT116 cells. Representative micrographs are shown (scale bar, 5μιη). Images are representative of at least 3 independent experiments. Then, frequencies of cell-in-cell structures induced by ATP or UTP supplementations in HCT1 16 in presence or in absence of 20 μΜ of ROCK inhibitor (Y27632), of 100 μΜ pan-caspase inhibitor (zVAD) or 20 μΜ of P2Y2 inhibitor Kaempferol. The frequencies of cell-in-cell structures were determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, *p<0.001). (E-M) Analysis of purinergic receptor P2Y2 expression after senescent- induced stresses. P2Y2 expression was determined by immunoblot on WI38 cells after hypoxia (F), during culture of human primary keratinocytes (HEKn) after 3 passages (P3), 4 passages (P4) or 5 passages (P5) (G), after irradiation with indicated doses of human primary keratinocytes (HEKn) (H), after treatment of HCT1 16 cells with 10 μΜ CDDP or 4 gray γ-irradiation (IR) (I). Representative immunoblots of 3 independent experiments are shown. (J) Effects of pharmacological inhibition of P2Y2 on cellular cannibalism induced by replicative stress. Replicative stressed human primary fibroblasts were stained, mixed and cultured during 24 hours in presence or in absence of the 20 μΜ of P2Y2 inhibitor Kaempferol. The frequencies of cell-in-cell structures were determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, p<0.001). (K) Effects of P2Y2 depletion on cellular cannibalism observed after p53 or Δ133ρ53 depletions or p53 deletion. As previously described, HCT116 cells that are depleted for P2Y2 and/or inactivated for p53 or Δ133ρ53 were stained, mixed and cultured during 24 hours in presence or in absence of 20 μΜ of Y27632 or 100 μΜ of zVAD. The frequencies of cell-in-cell structures were determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, *p<0.001).
Figure 12. Identification of entescence as a non-cell autonomous senescence. (A) Effects of P2Y2 inhibition on SA-β Gal activity of human primary keratinocytes. After the fifth passages, human primary keratinocytes were cultured during 24 hours in presence or in absence of 20 μΜ of P2Y2 inhibitor Kaempferol. The number of SA-β Gal positive single or cannibal cells per total number of cells examined (at least 300 per well) was recorded and frequencies of SA-β Gal positive were determined. Error bars represent means ± SEM (n = 3; *p < 0.01). (B) Effects of P2Y2 inhibition on SA-β Gal activity detected after g-irradiation or mithoxantron treatment. HCT116 cells were treated with 10 μΜ CDDP or 4 gray γ-irradiation (IR) and incubated during 24 hours in presence or in absence of 20 μΜ of P2Y2 inhibitor Kaempferol. Then as described above frequencies of SA-β Gal positive were determined (means ± SEM; n = 3; *p < 0.01). (C) Effects of P2Y2 depletion on SA-β Gal activity observed after coculture of p53+/+ or p53_/" HCT116 cells. As previously described, the number of SA-β Gal positive single or cannibal cells per total number of cells examined (at least 300 per well) was recorded (means ± SEM; n = 3; *p < 0.01). (E) Detection of DNA damage response (DDR) foci and p21WAF1 expression in single and cannibal cells after p53 or Δ133ρ53 inactivation. DNA damage response (DDR) foci were identified by γ-Η2ΑΧ (green), β-catenin (red) and Hoechst 33342 (blue) staining of internalizing HCT1 16 cells. P21WAF1 expression was also analyzed using antibody against p21WAF1 (green). Images are representative of at least three independent experiments (scale bar: 5μιη). (F-H) Effects of P2Y2 depletion on DNA damage foci formation, p21WAF1 expression and SA-β Gal activity detected after Δ133ρ53. After P2Y2 depletion, the percentage of Δ133ρ53 depleted cells showing positivity for γ-Η2ΑΧ+ or p21WAF1 expression were determined by confocal microscopy (G,H) and analyzed for β Gal activity (Means ± SEM; n = 3; *P < 0.01).
Figure 13. Detection of Entescence in vivo. (A) Representative image of primary breast adenocarcinoma stained for β-catenin (green) and nuclei (blue) is shown (a). Phase contrast is also shown (b). Arrow marks cannibal cell.n and χ respectively internalized nucleus and cannibal cell nucleus. (B) Representative image of primary breast adenocarcinoma stained for β-catenin (green), Lamp2 (red) and nuclei (blue) is shown in (a). Arrows indicate cannibal cells. Magnification of cannibal cell is shown in (b). (C) Quantification of cell-in-cell figures in normal primary breast (n=10) and in primary breast adenocarcinoma (n=30) biopsies (p<0.01). (D) Quantification of cell-in-cell figures in primary breast adenocarcinoma diagnosed for histological grade I (n=10), grade II (n=10) and grade III (n=10). (E) Representative images of primary breast adenocarcinoma obtained from patients treated with neo-adjuvant treatments stained by hematoxylin and eosin (HE). Four arrows mark cell-in-cell figures in (a). Magnifications of two representative images are shown in (b) and (c). (F) Representative image of primary breast adenocarcinoma biopsies obtained from patients treated with neo-adjuvant treatments stained for β-catenin (green), p21WAF1 (red) and nuclei (blue) is shown. (G) Quantification of p21WAF1 positive (p21WAF1+) single cells or cell-in-cell figures detected on neoadjuvant treated (n=15) or untreated primary breast adenocarcinoma biopsies (n=30) (p<0.001).
Figure 14. Levels of cellular cannibalism and entescence could help for the prediction of treatment efficiency in breast cancer. (A) Quantification of cell-in-cell figures in primary breast adenocarcinoma biopsies obtained from patients that are good (n=12) or bad (n=14) responders to neo-adjuvant treatment (p<0.001). (B) Kaplan-Meier disease free survival of neo-adjuvant treated patients. (C) Kaplan-Meier overall survival of neo-adjuvant treated patients. (D) Quantification of cell-in-cell figures in primary triple negative breast adenocarcinoma biopsies obtained from patients that are good or bad responders to neo-adjuvant treatment (p<0.001). (E)
Kaplan-Meier disease free survival of neo-adjuvant treated patients. (F) Kaplan-Meier overall survival of neo-adjuvant treated patients.
Figure 15. Depletion of Δ133ΤΡ53 isoform induces cellular cannibalism in p53 mutated cells. (A) Detection of cell-in-cell structures induced by depletion of Δ133ΤΡ53 in HT29 (^*21311) cells, as visualized by confocal microscopy. Cell-in-cell structures were identified by b-catenin (white), CMFDA (green) and CMTMR (red) staining of internalizing HCT116 cells. Images are representative of at least four independent experiments (scale bar in a, 5μιη and scale bar in b, Ι μιη). (B) Frequencies of cell-in-cell structures induced by Δ133ΤΡ53 knockdown, in HT29 cells in presence or in absence of 20 μΜ of ROCK inhibitor (Y27632) or 100 μΜ of pan- caspase inhibitor (zVAD). The frequencies of cell-in-cell structures were determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, p<0.001). Images are representative of at least four independent experiments (scale bar, 5μιη). (C) Effect of apyrase on cellular cannibalism. Cocultures of Δ133ΤΡ53 depleted HT29 cells in presence of different concentrations of apyrase were performed. Then, detection of cell-in-cell structures was performed by confocal microscopy (mean+/- s.e.m, n=3, p<0.001). (D) Effects of P2Y2 depletion on cellular cannibalism observed after Δ133ΤΡ53 depletion. As previously described, HT29 cells that are depleted for P2Y2 and/or inactivated for Δ133ΤΡ53 were stained, mixed and cultured during 24 hours. The frequencies of cell-in-cell structures were determined for at least 300 cells in 3 independent experiments (mean+/-s.e.m, *p<0.001). (E) Effects of cellular cannibalism on cell proliferation. After cell sorting, cell proliferation of Δ133ΤΡ53 knocked down single or cannibal HT29 cells were performed during 6 days. (F-I) Effects Δ133ΤΡ53 depletion on cellular cannibalism and on senescence induction of HT29 cells. Cannibal cells mediated Δ133ΤΡ53 knockdown were examined in EdU incorporation assay (F), in p21 expression assay (F) and in SA-P-Gal assay (G). (F) Determination of EdU incorporation on
cannibal cells induced by Δ133ΤΡ53 knockdown. Cell-in-cell structures were identified by β- catenin (red) and Hoechst 33342 (blue) staining of internalizing HT29 cells. EdU positive cells are green. Images are representative of at least three independent experiments (scale bar: 5μιη). The detection of p21WAF1 expression in single and cannibal HT29 cells after Δ133ΤΡ53 inactivation was also shown in (F). P21WAF1 expression (white), β-catenin (red) and Hoechst 33342 (blue) staining of internalizing HCT116 cells is shown. Images are representative of at least three independent experiments (scale bar: 5μιη). Arrow show cannibal cells. (G) Representative picture of SA-β Gal staining of single and cannibal cells obtained after Δ133ΤΡ53 inactivation is shown. Arrow indicates cannibal cell (H) Determination of EdU incorporation in single and cannibal cells after Δ133ΤΡ53 inactivation. The number of EdU positive single or cannibal HT29 cells per total number of cells examined (at least 300 per well) was recorded (n=3). (F) Quantification of p21WAF1 positive cells and SA-β Gal positive cells obtained after Δ133ΤΡ53 inactivation in cannibal cells after TP53 or Δ133ΤΡ53 inactivation are shown. The percentage of p21WAF1+ cells or SA-β Gal + cells were determined by confocal microscopy or by light microscopy. Error bars represent means ± SEM (n = 3; **P < 0.001).
DETAILLED DESCRIPTION OF THE INVENTION
Cancer cells are characterized by several acquired capabilities that allow them to sustain proliferative signaling, to evade growth suppressors, to resist to cell death, to enable replicative immortality, to reprogram energy metabolism, to induce angiogenesis, to escape immune system and to activate invasion (and metastasis) {Hanahan, Cell 2000;
Hanahan, Cell 2011 } . Signaling interactions between cancer cells and the tumor microenvironment cells (such as fibroblasts or immune cells) also contribute to cancer pathogenesis {Hanahan, Cell 2011 } . Inactivation of tumor suppressor genes (such as
p53) that is frequently detected in human tumors {Hanahan, Cell 2000; Hanahan, Cell 2011 } contributes to the acquisition of theses cancer cell capabilities, but also impacts tumor pathogenesis by modulating signaling networks in the tumor microenvironment {Hanahan, Cell 2011 } . The tumor suppressor gene p53 (that is mutated in approximately half of human tumors) promotes a variety of cellular responses depending on the type of tissue, the nature of the stress signal and the cellular microenvironment {Vousden, Nature reviews Molecular cell biology 2009} . P53 promotes cell survival activity through the activation of survival signaling pathways {Janicke, Cell Death Differ 2008 }, the protection against DNA damage {Bensaad, Cell 2006}, the modulation of energy metabolism {Tolstonog, PNAS 2010;Gottlieb, Cold Spring Harb Perspect Biol 2010} and antioxidant activities {Sablina, The Journal of biological chemistry 2005} . In addition, the signaling pathways operating upstream or downstream p53 can be interrupted in numerous tumors, suggesting that the pathways organized around p53 are critical for oncogenesis and tumor progression {Vogelstein, Nature 2000} . In response to a wide range of cellular stresses (including genotoxic damages, deregulated oncogenes, loss of cell contacts and hypoxia), p53 provides the elimination of cancer cells by stopping their developments (through anti- angiogenic activities {Tasdemir, J Mol Med 2007} or inhibition of their migration and invasion functions {Gadea, EMBO J. 2002; Gadea, J Cell Biol. 2007; Cartier-Michaud, PLoS One 2012}), by inducing cell death {Yonish-Rouach, Nature 1991 } or by promoting senescence {Vousden, Cell 2007; Vousden, Nature reviews Cancer 2002}). Recent counterintuitive works reveal that p53 may also exert its activity through non- cell autonomous function by modifying senescent associated secreted profil (SASP)
secretion {Coppe, PLoS Biol 2008} and by repressing in some circumstances cellular senescence {Demidenko, PNAS 2010} .
The N-terminal iso forms that lacked the transactivating domain (Δ40ΤΡ53 and Δ133ΤΡ53) act as dominant-negative regulators of p53 activity, and Δ133ΤΡ53 silencing has been associated with replication-induced senescence in normal human fibroblasts through enhanced transcriptional regulation of p53 -target genes, such as p21WAF1 and mir-34a (Fujita et al, Nat Cell Biol 2009).
Despite the diversity of functions of p53, the role of p53 in cellular cannibalism has never been studied. In this context, the present inventors show here for the first time that the tumor suppressor TP53 and its Δ133ΤΡ53 isoform act as repressors of cellular cannibalism. Indeed, loss of TP53 or Δ133ΤΡ53 expression increases extracellular ATP release and the consequent activation of purinergic P2Y2 receptors which signals for engulfment. They further demonstrate that cannibal cells activate a senescence program through p21WAF1 induction, unrevealing a new modality of induction of cellular senescence that can occur in the absence of TP53 or Δ133ΤΡ53. Senescence induced by oncogenic RasV12 and by replicative or oxidative stresses also results in cellular cannibalism, unrevealing that cannibalism is a common feature of senescent cells. Accordingly, cannibal cells found in human breast carcinomas exhibited signs of p21WAF1 activation. Altogether, these results provide evidence that cellular cannibalism and senescence are tightly linked in human cancer.
Moreover, the present inventors reveal that loss of p53 triggers an unsuspected senescent process that requires cell-in-cell internalization and entotic mechanisms to occur. This non-cell autonomous senescent process was called "entescence". It is observed during senescence-induced stresses (such oncogenic stimuli, replicative stresses, chemo- or radiotherapies) and in human tumors. In addition, they also demonstrate that senescence induced in cell autonomous manner also results in cellular cannibalism revealing that cellular cannibalism is a common feature of senescent cells. These results underscore the interplay between cellular cannibalism and senescence.
Definitions For performing the different steps of the method of the present invention, there may be employed conventional molecular biology, microbiology and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, for example, Sambrook, Fitsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (referred to herein as "Sambrook et al, 1989"); DNA Cloning: A Practical Approach, Volumes I and II (D. N. Glover ed. 1985); Oligonucleotide Synthesis (M. J. Gait ed. 1984); Nucleic Acid Hybridization(B. D. Hames & S. J. Higgins, eds. 1984); Animal Cell Culture (R. I. Freshney, ed. 1986); Immobilized Cells and Enzymes (IRL Press, 1986); B. E. Perbal, A Practical Guide to Molecular Cloning (1984); F. M. Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1994). p53 (hereafter also referred to as TP53) is a protein of apparent molecular weight 53 kDa that functions as a transcription factor that, among other functions, regulates the
cell cycle and functions as a tumor suppressor as mentioned above. Other isoforms or variants of p53 have been identified (see Bourdon, Brit. J. Cancer, 2007). For example, two other members of p53 family, p63 and p73, which are encoded by distinct genes, have been identified (Kaghad et al, Cell 1997; and Yang et al. Mol. Cell 1998). Human p53 isoforms may also arise due to alternative promoter usage and alternative splicing. Alternative promoter usage, for example, can give rise to the expression of an N- terminally truncated p53 protein initiated at codon 133 (Δ133ρ53 or Δ133ΤΡ53). Adding to the complexity of p53 isoforms is the alternative splicing of intron 9 of the p53 gene to provide the isoforms ρ53β and ρ53γ. Combined with alternative promoter usage, this gives rise to the p53 isoforms: p53, ρ53β (p53beta), ρ53γ (p53gamma), Δ133ρ53 (deltal33p53), Δ133ρ53β (deltal33p53beta), and Δ133ρ53γ (delta33p53gamma). The use of an alternative promoter in intron 2 gives rise to the additional isoforms, Δ40ρ53 (delta40p53), Δ40ρ53β (delta40p53beta), and Δ40ρ53γ (delta40p53gamma). While the presence of these multiple p53 isoforms has been established, the biological function of these isoforms remains obscure. The present invention is based in part on an elucidation of the role for p53 and three of these isoforms, Δ133ρ53, ρ53β and ρ53γ, in the functions of cell senescence and cell cannibalism.
As used herein, the term "p53" refers generally to a protein of apparent molecular weight of 53kDa on SDS PAGE that functions as the tumor suppressor described above. The protein and nucleic sequences of the p53 protein from a variety of organisms from humans to Drosophila are known and are available in public databases, such as in accession numbers, NM 000546 (SEQ ID NO: l), NP 000537 (SEQ ID NO: l l, NM 011640 (SEQ ID NO:2) and NP 035770 (SEQ ID NO: 12, for the human and
mouse sequences respectively. It is also referred to as "p53a" or "p53alpha". It contains an entire transactivation domain (including TAD1, and TAD2), the PXXP domain, a DNA binding domain, the NLS and an entire oligomerisation domain in C-terminal.
The term "Δ133ρ53" or "deltal33p53" or "Δ133ΤΡ53" or "deltal33TP53" refers generally to the isoform of p53 that arises from initiation of transcription of the p53 gene from codon 133, which results in an N-terminally truncated p53 protein. This isoform comprises the following p53 protein domains: the majority of the DNA binding domain, the NLS, and the C-terminal sequence DQTSFQKENC {see Bourdon, Brit. J. Cancer, 2007). It has for example SEQ ID NO: 14. It is encoded for example by SEQ ID NO: 3.
The term "ρ53β" or "p53beta" refers generally to the isoform of p53 that arises from alternative splicing of intron 9 to provide a p53 isoform comprising the following p53 protein domains: TAD1, TAD2, prD, the DNA binding domain, the NLS, and the C- terminal sequence DQTSFQKENC (see Bourdon, Brit. J. Cancer, 2007). It has for example the sequence SEQ ID NO: 15. It is encoded for example by SEQ ID NO: 4.
The term "ρ53γ" or "p53gamma" refers generally to the isoform of p53 that arises from alternative splicing of intron 9 to provide a p53 isoform comprising the following p53 protein domains: TAD1, TAD2, prD, the DNA binding domain, the NLS, and the C- terminal sequence MLLDLRWCYFLINSS. It has for example the sequence SEQ ID NO: 16. It is encoded for example by SEQ ID NO: 5.
The term "Δ40ρ53" or "Δ40ΤΡ53" or "delta40p53" or "delta40TP53" refers generally to the isoform of p53 that arises from whole splicing of intron 9, no splicing of intron 2
and normal splicing of exons 1,3 and 11 to provide a p53 isoform comprising the following p53 protein domains: TAD2, PXXP, the DNA binding domain, the NLS, and the entire oligomerisation domain in C-terminal. It has for example the sequence SEQ ID NO: 13. It is encoded for example by SEQ ID NO: 6.
The term "promoting" as used, for example in the context of "promoting cannibalism," refers generally to conditions or agents which increase, induce, open, activate, facilitate, enhance activation, sensitize, agonize, or up regulate cell cannibalism.
"Inhibitors," "activators," and "modulators" of cellular cannibalism are used to refer to activating, inhibitory, or modulating molecules identified using the in vitro of the invention. Inhibitors are compounds that, decrease, prevent, or down regulate the expression of p53 isoforms. "Activators" are compounds that increase, facilitate, or up regulate activity of p53 isoforms. Inhibitors, activators, or modulators include naturally occurring and synthetic ligands, antagonists, agonists, antibodies, peptides, cyclic peptides, nucleic acids, antisense molecules, ribozymes, RNAi molecules, small organic molecules and the like. Such assays for inhibitors and activators include, e.g., expressing p53 isoforms in vitro, in cells, or cell extracts, applying putative modulator compounds, and then determining the functional effects on p53 expression, as described below. The term "test compound" or "drug candidate" or "modulator" or grammatical equivalents as used herein describes any molecule, either naturally occurring or synthetic, e.g., protein, oligopeptide (e.g., from about 5 to about 25 amino acids in length, preferably from about 10 to 20 or 12 to 18 amino acids in length, preferably 12, 15, or 18 amino acids in length), small organic molecule, polysaccharide, peptide, circular peptide, lipid, fatty acid, siRNA, polynucleotide, oligonucleotide, etc., to be
tested for the capacity to directly or indirectly modulate p53 isoforms. The test compound can be in the form of a library of test compounds, such as a combinatorial or randomized library that provides a sufficient range of diversity. Test compounds are optionally linked to a fusion partner, e.g., targeting compounds, rescue compounds, dimerization compounds, stabilizing compounds, addressable compounds, and other functional moieties. Conventionally, new chemical entities with useful properties are generated by identifying a test compound (called a "lead compound") with some desirable property or activity, e.g., inhibiting activity, creating variants of the lead compound, and evaluating the property and activity of those variant compounds. Often, high throughput screening (HTS) methods are employed for such an analysis.
A "small organic molecule" refers to an organic molecule, either naturally occurring or synthetic, that has a molecular weight of more than about 50 daltons and less than about 2500 daltons, preferably less than about 2000 daltons, preferably between about 100 to about 1000 daltons, more preferably between about 200 to about 500 daltons.
Most of the methods of the invention are performed in vitro. As disclosed herein, the terms "m vitro" and "ex vivo" are equivalent and refer to studies or experiments that are conducted using biological components (e.g. cells or population of cells) that have been isolated from their usual host organisms (e.g. animals or humans). Such isolated cells can be further purified, cultured or directly analyzed to assess the presence of the mutant proteins. These experiments can be for example reduced to practice in laboratory materials such as tubes, flasks, wells, eppendorfs, etc. In contrast, the term "in vivo " refers to studies that are conducted on whole living organisms.
The screening methods of the invention are preferably performed on cell samples expressing p53 isoforms. In the context of the invention, these cell samples contain for example cell lines that are known to express one or the other isoforms. In a preferred embodiment, these cell lines are primary human diploid WI38 fibroblasts or cancer cell lines such as colorectal HCT116 carcinoma or pancreatic PANC813 cells.
The prognosis methods of the invention are preferably performed on a biological sample obtained from a patient in need thereof. As used in the context of these methods, the term "biological sample" advantageously refers to a serum sample, a plasma sample, a blood sample, a lymph sample, or to a tumor tissue sample obtained by biopsy. Preferably, the said biological sample is a blood sample or a tumor tissue sample obtained from a tumor biopsy. Said tissue sample is for example a tumor sample obtained from a primary breast adenocarcinoma, a primary cervical adenocarcinoma, a primary pancreatic adenocarcinoma, a primary melanoma, primary spitz tumors, a primary stomach or liver carcinoma. The prognosis method of the invention can include the steps consisting of obtaining a biological sample from said subject and extracting the nucleic acid from said biological sample. The DNA can be extracted using any known method in the state of the art. The R A can also be isolated, for example from tissues obtained during a biopsy, using standard methods well known to those skilled in the art, such as extraction by guanidium-thiophenate-phenol-chloroform.
The expression level of a protein in a biological sample is determined by:
- a method including a PCR, qPCR, a RT-PCR method, in situ hybridization, a Northern method or microarrays when the expression level of RNA transcripts encoding a defined protein is to be determined; or
Enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, immunofluorescence method, electron method or Enzyme-linked staining method for microscopic detection (e.g., immunohistochemistry assay), or flow cytometry, when the expression level of the protein itself is to be determined.
Such methods are well known from the skilled person (see e.g., Current Protocols in Molecular Biology, John Wiley & Sons, Inc. (1994). In a preferred embodiment, quantitative RT-PCR (qPCR) analysis can be used to measure the mRNA expression levels in a biological sample. Gene expression analysis by real-time quantitative PCR (RT- qPCR) is well known from the skilled person. For example, p53 mRNA expression analysis by RT-qPCR can be assessed after standard tissue sample RNA extraction (for example, the samples can be lysed in a tris-chloride, EDTA, sodium dodecyl sulphate and proteinase K containing buffer; RNA can be then extracted with phenol-chloroform-isoamyl alcohol followed by precipitation with isopropanol in the presence of glycogen and sodium acetate ; RNA can be resuspended in diethyl pyrocarbonate water (Ambion Inc., Austin, TX) and treated with DNAse I (Ambion Inc., Austin, TX) to avoid DNA contamination; complementary DNA can be synthesized using for example Maloney Murine Leukemia Virus retrotranscriptase enzyme; template cDNA can be added to Taqman Universal Master Mix (AB, Applied Biosystems, Foster City, CA) with specific primers and probe for each p53 iso forms.
The primer and probe sets can be designed using Primer Express 2.0 Software (AB) and the reference sequences (which can be obtained on the web site http://www.ncbi.nlm.nih.gov/entrez/query. fcgi?db=gene). Nucleic acid probes and primers for hybridizing specifically the mRNA or cDNA of p53 isoforms are well- known in the art. They are typically of at least 10, 15 or 20 nucleotides in length that is sufficient to specifically hybridize under stringent conditions to the mRNA or cDNA of p53 isoforms, or complementary sequence thereof (preferred are oligonucleotide primers or probe having at least 90 %, 95 %, 99 % and 100 % identity with the mRNA sequence fragment of the p53 isoforms or the complementary sequence thereof). Protein expression levels can be for example detected using antibodies specifically directed against different specific regions or epitope of the p53 protein and isoforms thereof. The term "antibody" as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site which specifically binds (or immunoreacts with) the p53 protein or isoforms thereof. The term "antibody" comprises monoclonal or polyclonal antibodies but also chimeric or humanized antibodies. These antibodies preferably differently bind the different isoforms of p53. These antibodies are for example the commercial mouse monoclonal DO-1 and DO-7 (recognizing specifically the ρ53β and ρ53γ isoforms), the commercial mouse monoclonal 1801 (recognizing all p53 isoforms except Δ133ρ53, the commercial mouse monoclonal antibodies BP53.10, 421, and ICA- 9 (that are specific for the a isoforms of p53 (p53, Δ40ρ53, and Δ133ρ53), because their epitopes are localized in the basic region (BR) of the p53 protein), and the rabbit polyclonal antibodies KJC8 (recognizing specifically ρ53β) and MAP4.9 (recognizing
specifically A133p53)(see Khoury M.P. and Bourdon J.C., Cold Spring Harb Perspect Biol. 2010;).
Preferably, the antibodies and probes used in the methods of the invention are labeled so as to be easily detected. The term "labeled", with regard to a probe or an antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently labeled streptavidin.
In the screening methods of the invention, cells expressing various p53 isoforms are treated with potential activators, inhibitors, or modulators so as to examine the extent of p53 isoform expression level modulation. In this case, "control levels" correspond to p53 isoform expression levels and/or ATP release and /or P2Y2R expression or activity levels measured in control cells, said control cells preferably being the same cells that have not been treated with said activators, inhibitors, or modulators. Therefore, control levels correspond to p53 isoform and/or ATP and /or P2Y2R expression levels measured in non-treated cells. In a particular embodiment, control samples (untreated) can be assigned a relative protein expression value of 100%. In this case, decrease (or repression) of the expression (or expression level) of a target protein would be achieved when the
expression level of said protein is of about 80%, preferably 50%>, more preferably 25- 0% relative to the control level. Conversely, increase (or promotion) of the expression (or expression level) of a target protein would be achieved when the expression level of said protein is at least of about 1 10%), more preferably at least of about 150%, and is more preferably of 200- 500% (i.e., two to five fold superior to the control), more preferably of 1000-3000% relative to the control level.
Also, as used in the present application, a "low" expression of a target protein is achieved when the expression level of said protein is less than about 80%>, preferably less than about 50%, more preferably less than about 25 % relative to the control level. Conversely, a "high" expression of a target protein is achieved when the expression level of said protein is at least of about 1 10%), more preferably at least of about 150%, and is more preferably of 200- 500% relative to the control level, i.e., from two to five folds superior to the control level.
In the prognosis methods of the invention, the p53 isoform or P2Y2R expression levels measured in the tumor cells of the patients are compared with "control level(s)". These control levels are preferably measured in normal cells or in non-treated tumor cells of the same patient, more preferably in normal cells of at least one another subject, preferably of an healthy subject.
Adenosine-5 '-triphosphate (ATP) is a nucleoside triphosphate used in all living cells for intracellular energy transfer. It is one of the end products of photophosphorylation, cellular respiration, and fermentation and used by enzymes and structural proteins in many cellular processes, including biosynthetic reactions, motility, and cell division. One molecule of ATP contains three phosphate groups. The structure of this molecule
consists of a purine base (adenine) attached to the Γ carbon atom of a pentose sugar (ribose). Three phosphate groups are attached at the 5' carbon atom of the pentose sugar. It is produced by a wide variety of enzymes, including ATP synthase, from adenosine diphosphate (ADP) or adenosine monophosphate (AMP) and various phosphate group donors.
ATP has the formula I :
ATP is typically quantified by measuring the light produced through its reaction with the naturally occurring firefly enzyme lucif erase using a lumino meter. The amount of light produced is directly proportional to the amount of ATP present in the sample. Extracellular ATP can be measured easily by a number of commercial kits (e.g., the Enliten ATP assay system of Promega). High-Performance liquid chromatography (HPLC) may also be used to measure extracellular levels of ATP.
The P2Y2 purinergic receptor, also known as "P2Y purinoceptor 2" or "P2Y2R" is a protein that in humans is encoded by the P2RY2 gene located on the chromosome 1 1 (Parr CE. et al, 1994, PNAS 1991). This receptor belongs to the family of G-protein coupled receptors. It favors the production of both the adenosine and uridine nucleotides. It may participate in control of the cell cycle of several cancer cells. In human, three transcript variants encoding the same protein have been identified for this
gene. These transcripts have the sequence SEQ ID N0:7 (variant 1), SEQ ID N0:8 (variant 2) and SEQ ID N0:9 (variant 3). The human P2Y2 purinergic receptor has the polypeptide sequence SEQ ID NO: 10. siRNAs are described for example in WO 02/44 321 (MIT/MAX PLANCK INSTITUTE). This application describes a double strand RNA (or oligonucleotides of same type, chemically synthesized) of which each strand has a length of 19 to 25 nucleotides and is capable of specifically inhibiting the post-transcriptional expression of a target gene via an RNA interference process in order to determine the function of a gene and to modulate this function in a cell or body. Also, WO 00/44895 (BIOPHARMA) concerns a method for inhibiting the expression of a given target gene in a eukaryote cell in vitro, in which a dsRNA formed of two separate single strand RNAs is inserted into the cell, one strand of the dsRNA having a region complementary to the target gene, characterized in that the complementary region has at least 25 successive pairs of nucleotides. Persons skilled in the art may refer to the teaching contained in these documents to prepare the siRNAs of the invention.
MicroRNAs (hereafter referred to as miRNAs) are small non-coding RNA molecule (ca. 22 nucleotides) found in plants and animals, which functions in transcriptional and post- transcriptional regulation of gene expression. miRNAs function via base-pairing with complementary sequences within mRNA molecules, usually resulting in gene silencing via translational repression or target degradation. miRNAs have been proposed in therapeutic strategies for treating cancer and acute ischemic diseases (Li C. et al, AAPSJ, 2009; Fasanaro et al, Pharmacol. Ther. 2010).
By "pharmaceutically acceptable vehicle", it is herein designated any and all solvents,
buffers, salt solutions, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. The type of carrier can be selected based upon the intended route of administration. In various embodiments, the carrier is suitable for intravenous, intraperitoneal, subcutaneous, intramuscular, topical, transdermal or oral administration. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. The use of media and agents for pharmaceutically active substances is well known in the art. An "effective amount" herein refers to an amount that is effective, at dosages and for periods of time necessary, to achieve the desired result, i.e., to treat effectively the patient. An effective amount as meant herein should also not have any toxic or detrimental severe effects.
Screening methods for identifying modulators of cellular cannibalism and senescence
In a first aspect, the present invention provides methods for identifying compounds that modulate cell cannibalism via its effect on p53 or Δ133ρ53. In general, the method includes these steps: (a) contacting a candidate compound with a sample that comprises p53 or Δ133ρ53, and (b) determining the functional effect of the candidate compound on the expression level of p53 or Δ133ρ53, based on which one may determine whether the said compound is an activator or an inhibitor of cellular cannibalism.
In one embodiment, the present invention relates to a method of identifying a compound that modulates cellular cannibalism, comprising the steps of:
(a) adding a compound to a cell culture in vitro,
(b) measuring in said culture the expression level of a protein selected from the group consisting of p53 and N-terminal isoforms of p53 that lack the N-terminal transactivating domain, such as Δ40ΤΡ53 and Δ133ΤΡ53; wherein a compound that represses cellular cannibalism is identified by a normal expression or an increase in the expression levels of p53 or said isoforms, as compared to control levels. Preferably, the said compound increases cellular cannibalism if the expression level of p53 or said isoforms decreases, as compared to control levels.
By "normal expression", it is herein meant that the expression of p53 or of its N- terminal isoforms lacking the N-terminal transactivating domain is almost identical (± 5%) to the control levels. More preferably, in this embodiment, said cell culture contains or consists of primary human diploid WI38 fibroblasts, or cancer cell lines such as colorectal HCT1 16 carcinoma or pancreatic ductal PANC813 adenocarcinoma.
Even more preferably, in this method, p53 is the polypeptide of SEQ ID NOl l, Δ40ΤΡ53 is the polypeptide of SEQ ID NO: 13, and Δ133ΤΡ53 is the polypeptide of SEQ ID NO: 14.
In another embodiment, the present invention relates to a method of identifying a compound that modulates cellular cannibalism, comprising the steps of:
(a) adding a compound to a cell culture in vitro,
(b) measuring in said culture the expression level of a protein selected from the group consisting of ρ53β and ρ53γ, wherein a compound that represses cellular cannibalism is identified by a decrease in the expression levels of ρ53β and/or ρ53γ, as compared to control levels.
Preferably, the said compound increases cellular cannibalism if the expression levels of ρ53β and ρ53γ are increased as compared to control levels. More preferably, s in this embodiment, said cell culture contains or consists of primary human diploid WI38 fibroblasts or cancer cell lines such as colorectal HCT1 16 carcinoma or pancreatic ductal PANC813 adenocarcinoma.
Even more preferably, in this method, ρ53β is the polypeptide of SEQ ID NO: 15 and ρ53γ is the polypeptide of SEQ ID NO: 16. In another embodiment, the present invention relates to a method of identifying a compound that modulates cellular cannibalism, comprising the steps of:
(a) adding a compound to a cell culture in vitro,
(b) measuring in said culture the extracellular amount of ATP, wherein a compound that represses cellular cannibalism is identified by a decrease in the extracellular amount of ATP, as compared to control levels.
Preferably, said compound increases cellular cannibalism if the extracellular amount of ATP, is increased as compared to control levels.
More preferably, in this embodiment, said cell culture contains or consists of primary human diploid WI38 fibroblasts or cancer cell lines such as colorectal HCT1 16 carcinoma or pancreatic ductal PANC813 adenocarcinoma.
In another embodiment, the present invention relates to a method of identifying a compound that modulates cellular cannibalism, comprising the steps of:
(a) adding a compound to a cell culture in vitro,
(b) measuring in said culture the expression level or the activity of the purinergic P2Y2 receptor, wherein a compound that represses cellular cannibalism is identified by a decrease in the expression level or in the activity of the purinergic P2Y2 receptor, as compared to control levels.
Preferably, said compound increases cellular cannibalism if the expression level or the activity of the purinergic P2Y2 receptor increases, as compared to control levels.
In this method, the expression level of purinergic P2Y2 receptor may be measured as defined above, that is, by measuring the mR A level or the protein level of the said receptor in the cells.
Alternatively, this method may involve the measurement of the activity of the purinergic P2Y2 receptor. By "activity", it is herein mean the "biological activity" of the said receptor. P2Y2 receptor biological activity is triggered by the binding of
extracellular nucleotides (such as ATP and UTP) and is coupled to intracellular signaling pathways through heterotrimeric G proteins activation and formation of a polyprotein complex that activates kinases (such as the proline-rich tyrosine kinase 2 (Pyk2)) involved in numerous cellular functions like plasma membrane permeabilization, Ca2+ influx and cytoskeleton reorganization. It can be detected for example by determining the phosphorylation of Pyk2 on tyrosine 402, one cellular consequence of P2Y2 biological activity (Seror et al, The Journal of experimental medicine 2011).
More preferably, in this embodiment, said cell culture contains or consists of primary human diploid WI38 fibroblasts or cancer cell lines such as colorectal HCT1 16 carcinoma or pancreatic ductal PANC813 adenocarcinoma..
Even more preferably, in this method, the purinergic P2Y2 receptor is the polypeptide of SEQ ID NO: 10.
Of course, a combination of the above-mentioned steps can be used to identify compounds that modulate cellular cannibalism.
Consequently, the present invention also relates to a screening method comprising the step of measuring in a cell culture:
• the expression level of a protein selected from the group consisting of p53 and N-terminal iso forms of p53 that lack the N-terminal transactivating domain, such as Δ40ΤΡ53 and Δ133ΤΡ53, and
• the expression level or the activity of the purinergic P2Y2 receptor,
wherein the tested compound represses cellular cannibalism if the expression levels of p53 or said iso forms increase, as compared to control levels, and if the expression level or the activity of the purinergic P2Y2 receptor decreases, as compared to control levels.
In a preferred embodiment, the tested compound increases cellular cannibalism if the expression levels of p53 or said iso forms decrease, as compared to control levels, and if the expression level of the purinergic P2Y2 receptor or the activity increases, as compared to control levels.
More preferably, in this embodiment, said cell culture contains or consists of primary human diploid WI38 fibroblasts or cancer cell lines such as colorectal HCT1 16 carcinoma or pancreatic ductal PANC813 adenocarcinoma.
The present invention also relates to a method of identifying a compound that modulates cellular cannibalism, comprising the step of measuring in a cell culture:
• the expression level of a protein selected from the group consisting of p53 and N-terminal iso forms of p53 that lack the N-terminal transactivating domain, such as Δ40ΤΡ53 and Δ133ΤΡ53, and
• the extracellular amount of ATP, wherein a compound that represses cellular cannibalism is identified by an increase in the expression levels of p53 or said isoforms, as compared to control levels, and a decrease in the extracellular amount of ATP, as compared to control levels.
In a preferred embodiment, the tested compound increases cellular cannibalism if the expression levels of p53 or said isoforms decrease, as compared to control levels, and if the extracellular amount of ATP increases, as compared to control levels.
More preferably, in this embodiment, said cell culture contains or consists of primary human diploid WI38 fibroblasts or cancer cell lines such as colorectal HCT1 16 carcinoma or pancreatic ductal PANC813 adenocarcinoma.
The present invention also relates to a method of identifying a compound that modulates cellular cannibalism, comprising the step of measuring in a cell culture:
• the expression level of a protein selected from the group consisting of p53 and N-terminal isoforms of p53 that lack the N-terminal transactivating domain, such as Δ40ΤΡ53 and Δ133ΤΡ53,
• the expression level or the activity of the purinergic P2Y2 receptor and
• the extracellular amount of ATP, wherein a compound that represses cellular cannibalism is identified by an increase in the expression levels of p53 or said isoforms, as compared to control levels, and a decrease in both the extracellular amount of ATP, and in the expression level or the activity of the purinergic P2Y2 receptor, as compared to control levels.
In a preferred embodiment, the tested compound increases cellular cannibalism if the expression levels of p53 or said isoforms decrease, as compared to control levels, and if the extracellular amount of ATP increases as compared to control levels, and if the expression level or the activity of the purinergic P2Y2 receptor increases, as compared to control levels.
More preferably, in this embodiment, said cell culture contains or consists of primary human diploid WI38 fibroblasts or cancer cell lines such as colorectal HCT1 16 carcinoma or pancreatic ductal PANC813 adenocarcinoma.
In a preferred embodiment, measuring expression levels of the p53 isoforms protein or of the P2Y2 receptor comprises measuring the mR A levels of these proteins. In a more preferred embodiment, measuring expression levels of the p53 isoform protein or of the P2Y2 receptor comprises using a transcriptional fusion between said p53 isoform or receptor and a reporter molecule.
In vitro methods for detecting cannibalism behavior of a cell
So far, this activity was commonly assessed by studying the cells under the microscope (by immunofluorescence or immunohistochemistry) and by visually detecting cell engulfment events or cell-in-cell systems.
The present inventors have shown in the experimental part of the present application that it is possible to detect early events of a cannibalism behavior of a cell, by measuring, in said cell, the expression level of a protein selected from the group consisting of: p53, ρ53β, ρ53γ, and N-terminal isoforms of p53 that lack the N-terminal transactivating domain, such as Δ40ΤΡ53 and Δ133ΤΡ53, or by measuring the expression level or the activity of the purinergic P2Y2 receptor, and/or by measuring the extracellular ATP secreted by said cells.
Study of these molecular pathways therefore results in a fine analysis of the early mechanisms resulting in cannibalistic activity, before the morphologic events usually attributed to engulfing activity can be observed.
Thus, in another aspect, the present invention relates to an in vitro method for detecting cannibalism behavior of a cell, comprising the step of measuring in said cell:
• the expression level of a protein selected from the group consisting of p53 and N-terminal iso forms of p53 that lack the N-terminal transactivating domain, such as Δ40ΤΡ53 and Δ133ΤΡ53, and/or
• the expression level or the activity of the purinergic P2Y2 receptor, and/or
• secreted extracellular ATP, and/or
• the expression level of a protein selected from the group consisting of ρ53β and ρ53γ, wherein the said cell has cannibalism activity if the expression levels of p53 or said Δ40ΤΡ53 and Δ133ΤΡ53 isoforms is low, and/or if secretion of extracellular ATP is high, and/or if the expression level or the activity of the purinergic P2Y2 receptor is high, and/or if the expression level of ρ53β or ρ53γ is high, as compared to control levels.
Preferably, the said cell has no cannibalism activity if the expression levels of p53 or said Δ40ΤΡ53 and Δ133ΤΡ53 isoforms is high, and/or if secretion of extracellular ATP by said cell is low, and/or if the expression level or the activity of the purinergic P2Y2
receptor is low, and/or if the expression level of ρ53β or ρ53γ is low, as compared to control levels.
In a preferred embodiment, the method of the invention further comprises the step of measuring at least one senescence marker, for example selected from the group consisting of: p21WAF1, Ki67, pi 6, Rb, and SA-P-Gal. It is also possible to detect the senescent morphology of the cells by microscopic analysis, for example the increase of cell and nuclear sizes, the detection of senescent associated heterochromatin foci, or cell autophagy or the markers of growth arrest (for example an increase in pi 6), or the secretion of senescent associated secreted proteases (SASP), or markers of DNA damage responses (g-H2AX, ATMS1981P, p53BPl, etc.).
Thus, in a more preferred embodiment, the present invention relates to an in vitro method for detecting simultaneously cannibal and senescent behavior of a cell, comprising the step of detecting cellular cannibalism markers as mentioned in the present application and senescent markers disclosed above. More precisely, said method comprises the step of measuring, in said cell: the expression level of a protein selected from the group consisting of p53 and N-terminal iso forms of p53 that lack the N-terminal transactivating domain, such as Δ40ΤΡ53 and Δ133ΤΡ53, and/or the expression level or the activity of the purinergic P2Y2 receptor, and/or
secreted extracellular ATP, and/or
the expression level of a protein selected from the group consisting of ρ53β and ρ53γ, and
• the expression level of at least one senescence marker such as p21 , Ki67, pl6, Rb, or SA-P-Gal, wherein the said cell has cannibal activity and undergo senescence if the expression levels of p53 or said Δ40ΤΡ53 and Δ133ΤΡ53 isoforms are low, and/or if secretion of extracellular ATP is high, and/or if the expression level or the activity of the purinergic P2Y2 receptor is high, and/or if the expression level of ρ53β or ρ53γ is high, and if the expression level of the senescence markers p21WAF1, pl6, and /or SA-P-Gal is high or if the expression level of the senescence markers Ki67 and /or Rb is low compared to control levels. In another aspect, the present invention relates to an in vitro method of determining an increase in the propensity of a cell to be a target of cellular cannibalism.
The present inventors have indeed observed that any of the following events: (a) increased extracellular release of ATP, (b) decreased p53 expression, (c) decreased Δ133ΤΡ53 expression, (d) increased expression of ρ53β or ρ53γ, (e) increased expression of P2Y2 purigenic receptors, induces an increase in the propensity of a cell to be a target of cellular cannibalism.
As used herein, the expression "increase in the propensity of a cell to be a target of cellular cannibalism" means that there is an increase in the "eat-me" signals emitted by the cells. These signals are for example extracellular nucleotides such as ATP or UTP, that are known signals for cell engulfment.
In a preferred embodiment, measuring the expression levels of the said proteins comprises measuring their mRNA levels, for example by qPCR or by in situ
hybridization. Also, secreted ATP is preferably measured by HPLC or luciferase assays. In addition, biological activity of P2Y2R is preferably measured by determining the phosphorylation of Pyk2 on tyrosine 402 (Seror et al. The Journal of experimental medicine 2011).
In vitro methods for inducing cellular cannibalism in a cell
The present inventors identified for the first time that low levels of p53, of Δ133ΤΡ53 or of Δ40ΤΡ53 promotes cellular cannibalism.
In another aspect, the present invention furthermore relates to a method of inducing cellular cannibalism in a cell in vitro, comprising inhibiting in said cell the expression of p53 or of an N-terminal isoform of TP53 selected from Δ133ΤΡ53 and Δ40ΤΡ53.
This inhibition may be obtained by inhibiting the formation of the said proteins (e.g., by inhibiting the transcription of DNA to mRNA or the translation of mRNA to a protein), or by promoting the degradation of these proteins by any conventional means. In particular, said expression inhibition may be mediated by inhibiting the translation of mRNA to a protein by means of a miRNA or a siRNA.
More specifically, the invention relates to double strand siRNAs of approximately 15 to 30 nucleotides, preferably 19 to 25 nucleotides, or preferably around 19 nucleotides in length that are complementary (strand 1) and identical (strand 2) to nucleotide regions of the p53 isoforms implicated in the methods of the invention. These siRNAs of the
invention may also comprise a dinucleotide TT or UU at the 3 ' end. Numerous computer programmes are available for the design of the siRNAs of the invention.
In one particular embodiment, the siRNAs of the invention are tested and selected for their capability of reducing, even specifically blocking the expression of one particular p53 isoform, affecting as little as possible the expression of the other isoforms. For example, the invention concerns siRNAs allowing a reduction of more than 80%, 90%, 95% or 99%) of the expression of one p53 isoform, and no reduction or a reduction of less than 50%, 25%, 15%, 10% or 5% or even 1% of the other isoforms of p53.
In a preferred embodiment, said p53 expression inhibition is achieved by using the siRNA of SEQ ΙΌΑ7 (siRNA-1 : 5 'GACUCCAGUGGUAAUCUAC 3 ') or SEQ ID NO: 18 (siRNA-2 :5 'GCAUGAACCGGAGGCCCAU 3 ')·
In another preferred embodiment, said Δ133ΤΡ53 expression inhibition is achieved by using the siRNA of SEQ ID NO: 19 (siRNA-1 : 5 'UGUUCACUUGUGCCCUGACUUUCAA3 ') or SEQ ID NO:20 (siRNA-2 : 5 'CUUGUGCCCUGACUUUCAA3 ').
These various siRNAs and miRNAs can be used for inducing simultaneously cell cannibalism and senescence in cancer cells. Consequently, they can be used for enhancing the survival of a patient suffering from cancer and, eventually, for treating cancer. The present invention therefore also relates to the use of these siRNAs and miRNAs for the preparation of a pharmaceutical composition which is intended to treat cancer. Said
pharmaceutical composition contains for example the said siRNAs or miRNAs and a pharmaceutically acceptable vehicle as defined above.
In other words, the present invention relates to a method for treating cancer, comprising the step of administering, in a patient suffering from cancer, an effective amount of any of the above-mentioned siRNAs or miRNAs.
These siRNAs can be injected into the cells or tissues by lipofection, transduction or electroporation.
In a related aspect, the present invention relates to a method of inhibiting cellular cannibalism in a cell in vitro, comprising inhibiting in said cell the expression of ρ53β or ρ53γ, or inhibiting the expression or the activity of the purinergic P2Y2 receptor, or inhibiting the secretion of extracellular ATP.
In a preferred embodiment, the expression of the isoforms ρ53β or ρ53γ, or of the purinergic P2Y2 receptor is inhibited by using a miRNA or a siRNA. P2Y2R expression inhibitors are for example disclosed in Seror C. et al, The Journal of experimental medicine 2011.
Again, these siRNAs can be double strand RNAs of approximately 15 to 30 nucleotides, preferably 19 to 25 nucleotides, or preferably around 19 nucleotides in length that are complementary (strand 1) and identical (strand 2) to nucleotide regions of the p53 isoforms ρ53β or ρ53γ or of the purinergic P2Y2 receptor. siRNAs inhibiting the expression of the P2Y2 receptor are for example those of SEQ ID NO:53 or of SEQ ID NO:54.
In one particular embodiment, the siRNAs of the invention are tested and selected for their capability of reducing, even specifically blocking the expression of ρ53β or ρ53γ, affecting as little as possible the expression of the other p53 isoforms. For example, the invention concerns siRNAs allowing a reduction of more than 80%, 90%, 95% or 99% of the expression of ρ53β or of ρ53γ, and no reduction or a reduction of less than 50%, 25%, 15%, 10% or 5% or even 1% of the other isoforms of p53.
Inhibition of P2Y2R biological activity can be obtained by using blocking agents such as low molecular weight antagonist (such as a small organic P2Y2R inhibitor kaempferol or other purinergic receptor antagonists including but not limited to reactive red 2, suramin, oxidized ATP, 8,8'-(carbonylbis(imino-3,l-phenylene carbonylimino)bis(l,3,5-naphthalenetrisulfonic acid) (also called NF023), 8,8'- (carbonylbis(imino-4, 1 -phenylenecarbonylimino-4, 1 - phenylenecarbonylimino))bis(l,3,5-naphthalenetrisulfonic acid) (also called NF279), Evans blue, trypan blue, reactive blue 2, pyridoxalphosphate-6-azophenyl-29,49- disulfonic acid (PPADS), isoquinoline sulfonamide, l-[N,0-bis(5-isoquinoline- sulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine (also called KN-62), trinitrophenyl- substituted nucleotides (e.g., TNP-ATP), diinosine pentaphosphate (IP5I), cicacron blue 3GA, 2*,3'-0-(2,4,6-trinitrophenyl)-ATP, substance P (SP), basilen blue, and 4,4*- diisothiocyanostilbene-2,2'-disulfonic acid, or combinations, derivatives, or pharmaceutically acceptable salts thereof), blocking antibodies or aptamers or siRNAs.
In another preferred embodiment, the secretion of ATP is inhibited by blocking the membrane channels known to be involved in ATP transport (such as pannexin-1 and
connexin-43) or by impairing biological mechanisms that are involved in same (such as autophagy or exocytosis) by means of conventional tools.
The present invention also concerns a therapeutic composition comprising a pharmaceutically acceptable vehicle and at least one of these compounds for its use for treating cancer.
Prognosis methods based on detection of cannibalism and senescence
Cellular cannibalism and cell senescence were both shown to be involved in tumorigenesis. However, their precise role with this respect remains controversial. On a one hand, cellular cannibalism was shown to promote tumor development. Tumor cell cannibalism has been therefore linked with poor tumor prognosis, what can be due to genomic instability induced in the polyploid cells (Krajcovic et al, 2011; Krajcovic and Overholtzer, 2012).
On another hand, cell senescence was shown to impair tumorigenesis (Cano CE, et al. EMBO Mol Med. 2012) or to promote same (Krajcovic et al, Nat Cell Biol 2011; Krajcovic and Overholtzer, Cancer Res 2012), so that the measure of senescence markers alone is of poor pronostic value.
The present inventors herein show for the first time that cellular cannibalism and senescence are tightly linked in human cancer and that the detection of both processes in cancer cells positively correlates with good patient's response to treatment. Importantly, their results provide the first evidence that detection of cellular cannibalism and
senescence simultaneously in tumors helps for the diagnosis of disease outcomes and for the prediction of treatment efficiency against cancer diseases.
In another aspect, the present invention therefore relates to an in vitro method of determining the prognosis of cancer in a patient, comprising the step of simultaneously detecting the cannibal and senescent behavior of the tumor cells of this patient. As a matter of fact, if the said tumor cells have simultaneously high cannibal and senescent activities, then the said tumor cells will be of good prognosis and the patient survival is likely to be long. In contrast thereto, if the said tumor cells have low (or no) cannibal and senescent activities, then the said tumor cells will be of bad prognosis and the patient survival is likely to be short.
In this aspect, the said method preferably comprises the step of measuring the expression levels of p53 or of one of its isoforms Δ133ΤΡ53, ΤΡ53β, ΤΡ53γ, or Δ40ΤΡ53, or the expression level or the activity of the purinergic P2Y2 receptor, and the expression level of a senescence marker such as p21WAF1, Ki67, pi 6, Rb, or SA-β- Gal, or of any other senescence marker as described above, in tumor cells isolated from the patient.
In fact, if the expression levels of p53 or said Δ40ΤΡ53 and Δ133ΤΡ53 isoforms in said tumor cells are low, or if the expression level or the activity of the purinergic P2Y2 receptor in said tumor cells is high, or if the expression level of ρ53β or ρ53γ in said tumor cells is high compared to control levels, and, simultaneously, if the expression level of the senescence markers p21WAF1, pl6, and /or SA-P-Gal is high or if the expression level of the senescence markers Ki67 and /or Rb is low, then said tumor cell
has high cannibal activity and undergo senescence, what is of good prognosis value for the patient.
In a preferred embodiment, the said method comprises the step of measuring the expression levels of p53 or of Δ133ΤΡ53, or the expression level or the activity of the purinergic P2Y2 receptor, and the expression level of a senescence marker such as p21WAF1, Ki67, pl6, Rb, or SA-P-Gal, or of any other senescence marker as described above, in tumor cells isolated from the patient.
In a more preferred embodiment, the said method comprises the step of measuring:
• the expression levels of p53 or of Δ133ΤΡ53, and
· the expression level or the activity of the purinergic P2Y2 receptor, and
• the expression level of a senescence marker such as p21WAF1, Ki67, pi 6, Rb, or SA-P-Gal, or of any other senescence marker as described above, in tumor cells isolated from the patient.
In another aspect, the present invention also relates to an in vitro method of determining the susceptibility of tumor cells to an anti-cancer treatment, comprising the step of detecting concomitantly the cannibal and senescent behavior of the said cells by means of the method of the invention, as defined above. As a matter of fact, if the said tumor cells exhibit simultaneously high cannibal and senescent activities after treatment, then the said tumor cells will be sensitive to the said anti-cancer treatment. In contrast thereto, if the said tumor cells have high cannibal activity but low or no senescent activity after treatment, then the said tumor cells will be resistant to the said anti-cancer treatment.
By "concomitantly" or "simultaneously", it is herein meant that the target processes occur in the cells from the same tumor. In particular, by using these terms, it is herein meant that the detection is performed in cells issued from the same tumor or patient, for example, from two tumor samples obtained from the same patient. As used herein, these terms do not mean that the measuring steps should be performed at the very same time, but rather on cell samples obtained from the same patient, preferably from the same tumor.
Said anti-cancer treatment is preferably a radiotherapeutic treatment, a chemotherapeutic treatment, an immunotherapeutic treatment, or a combination of same.
In these prognosis methods, the said tumor cells express normal levels or high levels of non-mutated p53.
In these prognosis methods, the said cancer is preferably selected in the group consisting of: melanoma, spitz tumors, prostate cancer, colon carcinoma, and liver carcinoma, breast cancer, lung cancer, cervical cancer, and bone cancer.
In another aspect, the present invention relates to treating methods comprising the steps of:
Determining the susceptibility of tumor cells to a defined anti-cancer treatment, by means of the prognosis method of the invention, and, if said tumor cells exhibit simultaneously high cannibal and senescent activities after treatment, then maintaining the said anti-cancer treatment.
Whereas, if said tumor cells have high cannibal activity but low or no senescent activity after treatment, then another anti-cancer treatment is to be administered.
For example, if the patient is treated with a defined chemotherapeutic treatment, determining the susceptibility of tumor cells to said treatment by means of the method of the invention will enable the skilled person to decide if the said chemotherapy is required or if it would be advantageous to replace - or to combine - it with radiotherapy or with another chemotherapeutic treatment.
In a particular aspect, the present invention relates to an in vitro method of determining the resistance of tumor cells to an anti-cancer treatment, comprising the step of detecting the cannibal and senescent behavior of the said cells by means of the method of the invention, as defined above. As a matter of fact, if the said tumor cells have high cannibal and senescent activities after treatment, then the said tumor cells will be sensitive to the said treatment. In contrast thereto, if the said cells have high cannibal activity but low or no senescent activity, then the said tumor cells will be resistant to the said anti-cancer treatment.
Said anti-cancer treatment is preferably a radiotherapeutic treatment, a chemotherapeutic treatment, an immunotherapeutic treatment, or a combination of same.
In this particular aspect, the said tumor cells preferably express mutated p53. These tumor cells are more preferably Triple Negative Breast Cancer (TNBC).
For this particular aspect, the present invention finally relates to treating methods comprising the steps of:
Determining the susceptibility of tumor cells to a defined anti-cancer treatment, by means of the prognosis method of the invention, and, if said tumor cells exhibit simultaneously high cannibal and senescent activities after treatment, then maintaining the said anti-cancer treatment.
Whereas, if said tumor cells have high cannibal activity but low or no senescent activity after treatment, then another anti-cancer treatment is to be administered.
For example, if the patient is treated with a defined chemotherapeutic treatment, determining the susceptibility of tumor cells to said treatment by means of the method of the invention will enable the skilled person to decide if the said chemotherapy is required or if it would be advantageous to replace - or to combine - it with radiotherapy or with another chemotherapeutic treatment.
In a preferred embodiment, all the prognosis methods of the invention comprises a step of detecting the cannibalism and / or senescence behavior of the tumor cells on paraffin- embedded tumor tissue samples by immunohistochemistry.
EXAMPLES
Cells, antibodies and reagents.
Colorectal carcinoma (Tp53+/+ and Τρδ^') HCT116 cells were cultured in McCoy's 5A medium. Non small cell lung carcinoma H1299 (ρ53 Λ), H1975, H1650, cervix adenocarcinoma HeLa cells, ostocarcinoma U20S cells and human fibroblasts WI38 were cultured in Dulbecco's modified Eagle's medium (DMEM). Colorectal adenocarcinoma HI 975 and HI 650 cells and primary ductal carcinoma HCC1937 (p53 A) cells, were in RPMI-1640 Medium. All medium were supplemented 10% FCS, 2mM L-glutamine and 100 Ul/ml penicillin/streptomycin (Invitrogen). Head and neck squamous cell carcinoma SQ20B (p53 ) cells and pancreatic PANC813 cells were cultured as previously described. All medium were supplemented 10% FCS, 2mM L-glutamine and 100 Ul/ml penicillin/streptomycin (Invitrogen). Human primary keratinocytes were cultured using KGM-Gold™ BulletKit™Kit (Lonza, 00192060). Antibodies for detection of ATM, ATR, BRCA-1, BRCA-2, β-catenin, cleaved caspase-3 (Asp 175), FOXO-1, FOXO-3, FOXO-4, LKB1, pl5INKb, p21WAF1, 53BP1, MLC2, MLC2S19*, PAR-4, PTEN, Rb, TP73 were obtained from Cell Signaling Technology. Beclin-1, LAMP2, and TP53 (clone DOl) were from Santa Cruz. Antibodies against γ-Η2ΑΧ and GAPDH were purchased from Millipore. Antibody against P2Y2 and TP53 (clone CM1) were respectively from Alomone laboratories and Leica. Constructs containing TP53WT, TP53NES", TP53NLS", TP53R175H, T ^1127311 or EGFP and control were previously published (Tasdemir et al., 2008). Plasmids containing ΤΡ53β, ΤΡ53γ, Δ40ΤΡ53 and Δ133ΤΡ53 were obtained from Jean-Christophe Bourdon (University of Dundee, UK).
RNA interference.
Small interfering RNAs (siRNAs) specific for ATM (siRNA-1 : 5'UGAAGUCCAUUGCUAAUCA3' and siRNA-2: 5'AACAUACUACUCAAAGACA3'), ATR
(siRNA-1 : 5'CCUCCGUGAUGUUGCUUGA3' and siRNA-2 : 5' GCCAAGACAAAUUCUGUGU 3'), BRCA1 (siRNA-1 : 5'GCAACCUGUCUCCACAAAG3' and siRNA-2 : 5'UGCCAAAGUAGCUAAUGUA3'), BRCA2 (siRNA-1 : 5'CUGAGCAAGCCUCAGUCAA3' and siRNA-2 : 5'CAACAAUUACGAACCAAAC3'), LKB1 (siRNA-1 : 5 'GGACUGACGUGUAGAACAA3 ' and siRNA-2 : 5' GUCCUUACGGCAAGGUGAA 3'), pl5INK4b (siRNA-1 : 5'CUCAGUGCAAACGCCUAGA3' and siRNA-
2 : 5'AACUCAGUGCAAACGCCUAGA3'), TP53 (siRNA-1: 5 'GACUCCAGUGGUAAUCUAC3 ' and siRNA-2 : 5 'GCAUGAACCGGAGGCCCAU3 '), TP63 ( siRNA-1 :
5'CCAUGAGCUGAGCCGUGAAU3' and siRNA-2 : 5 'AGCAGCAAGUUUCGGACAG3 '), TP73 (siRNA-1: 5 'CCACGAGCUCGGGAGGGAC3 ' and siRNA-2 : 5'ACGUCCAUGCUGGAAUCCG3'), Par-4 (siRNA-1 : 5'GUGGGUUCCCUAGAUAUAA3' and siRNA-2 :
5'CAGCCGUUUGAAUAUAUUU3'), PTEN (siRNA-1 : 5 'GUCAGAGGCGCUAUGUGUA3 ' and siRNA-2 : 5' CACCACAGCUAGAACUUAU 3 ' ), Rb (siRNA-1: 5 'GAAAGGACAUGUGAACUUA3 ' and siRNA-2 : 5'CGAAAUCAGUGUCCAUAAA3'), p21WAFl (siRNA-1 : 5'CUUCGACUUUGUCACCGAG3' and siRNA-2 : 5'CAGUUUGUGUGUCUUAAUUAU3'), Beclin- 1 (siRNA-1 : 5 'GAUUGAAGACACAGGAGGC3 ' and siRNA-2 :
5'CCACUCUGUGAGGAAUGCACAGAUA3'), FOXO-1 (siRNA-1 :
5 'GCCCUGGCUCUCACAGCAA3 ' and siRNA-2 : 5'CCGCGCAAGAGCAGCUCGU3'), FOXO-3 (siRNA-1 : 5'GGGCGACAGCAACAGCUCU3' and siRNA-2 : 5' GGAUGACGUCCAGGAUGAU3 '), FOXO-4 (siRNA-1 : 5'CCCGACCAGAGAUCGCUAA3' and siRNA-2 : 5 'GGACAAGGGUGACAGCAAC3 '), Δ133ΤΡ53 (siRNA-1 : 5'
UGUUCACUUGUGCCCUGACUUUCAA3 ' and siRNA-2 :5'
CUUGUGCCCUGACUUUCAA3 '), P2Y2 (siRNA-1 : 5' GGAUAGAAGAUGUGUUGGG3 ' and siRNA-2: 5' GGCUGUAACUUAUACUAAA3 ') and control sirRNA (5'- GCCGGUAUGCCGGUUAAGU-3') were transfected 48 hours before coculture using Oligofectamine (Invitrogen), according to manufacturer's instructions.
Pharmacological inhibitions.
After inactivation of TP53 or Δ133ΤΡ53, primary human fibroblasts, primary human keratinocytes, colorectal carcinoma Tp53+/+ HCT116 cells and pancreatic PANC813 cells were incubated during 24 hours in presence or in absence of indicated concentrations of the pharmacological inhibitor of purinergic P2Y2 receptor Kaempferol (Sigma), the pharmacological inhibitor of ROCK Y27632 (Sigma) or the pan-caspase inhibitor zVAD-fmk (lOOuM, BD Biosciences). ATP, UTP and soluble apyrase used in indicated experiments were obtained from Sigma.
I mmunoblots and immunofluorescence. Total cellular proteins were extracted in 250 mM NaCl-containing lysis buffer (250 mM NaCl, 0.1% NP40, 5 mM EDTA 10 mM Na3V04, 10 mM NaF, 5mM DTT, 3 mM Na4P207 and the protease inhibitor cocktail (EDTA-free protease inhibitor tablets, Roche). Protein extracts (50 μg) were run on 4-12%> SDS-PAGE and transferred at 4°C onto a nitrocellulose membrane. After blocking, membranes were incubated with primary antibody at room temperature overnight. Horse radish peroxidase-conjugated goat anti-mouse or anti-rabbit (Southern Biotechnology) antibodies were then incubated during 1 h and revealed with the enhanced ECL detection system. After 48 hours of transfection with specific indicated siRNA, cells were stained with 10 μΜ of 5-chloromethylfluorescein diacetate (Cell Tracker Green CMFDA, Invitrogen) or with 10 μΜ of 5-(and-6)-(((4- Chloromethyl)Benzoyl)Amino)Tetramethylrhodamine (CMTMR, Invitrogen) and cocultured for indicated time. Time-lapse microscopy was performed on 35mm on cover glass bottom dishes coated with poly-hema. Fluorescence and differential interference contrast (DIC) or phase contrast images were obtained every 5 min. For specific subcellular stainings of cannibal cells, cells were fixed in 4% paraformaldehyde/ phosphate-buffered saline (PBS) for 30 minutes, permeabihzed in 0.1 % SDS in PBS and incubated with FCS for 20 minutes, as
previously described (Seror et al., 2011). Antisera were used for immunodetection in PBS containing 1 mg/ml BSA and revealed with goat anti-rabbit IgG conjugated to Alexa 546 fluorochromes and with rabbit anti-mouse IgG conjuguated to Alexa 647 fluorochromes from Invitrogen. Cells were counterstained with Hoechst 33342 (Invitrogen) and analyzed by fluorescent confocal microscopy on a Zeiss LSM510 using a 63 x objective.
Electron microscopy.
After co-culturing of cell for 24h, cells were fixed in 1.6% glutaraldehyde in 0.1 M Sorensen phosphate buffer (pH 7.3) for 1 h at 4°C. cells were washed one time with PBS and were refixed in aqueous 2% osmium tetroxide and finally embedded in Epon® epoxy resin, until imaging. Examination is performed at 80 kV under a transmission electron microscopy, on ultrathin sections (80 nm) stained with 0.1% lead citrate and 10%> uranyl acetate.
Measurement of extracellular ATP.
ATP release was determined using the Enliten ATP assay system (Promega) as described by the manufacturer. The luminescence was measured by integration over a 3-s time interval using the luminometer Fluostar OPTIMA (BMG Labtech).
Cell proliferation assay.
Cancer cell lines (HCT116 WT, HCT116 Tp53' , PANC813) that stably expressed green or red fluorescent proteins in their nuclei (GFP-histone H2B and RFP-histone H2B fusion proteins) were generated and were cocultured during 24 hours, optionally after depletion of Δ133ΤΡ53 to induce cell-in-cell internalization. Cell-in-cell structures were seeded in microtiter plates (with one single structure per well) by cell sorting using BD Influx™ cell sorter (Becton Dickinson).
Sorted populations (single cell and cannibal cell) were validated under fluorescent microscope.
Then, single cells and cannibal cells were cultured for seven days. During seven days, number of structure (single cell or cannibal cell) were quantified daily.
Detection of senescence associated β galactosidase.
After co-culturing of 48h, cells were fixed and stained using the senescence β-galactosidase staining kit (Cell signaling technologies) to detect senescence associated β galactosidase (SA- PGal) activity as previously described (Matsuura et al., 2007). Cell cycle analysis.
To analyze cannibal cell proliferation, depleted cells were co-cultured for 24h and then incubated with 10 μΜ 5-ethynyl-2'-deoxyuridine (EdU) for lh and stained using the Click- iT™ Edu Imaging Kit from Invitrogen. The cells were also counterstained with an antibody against β catenin and with Hoechst 33342 to identify cannibal cells and the nuclei were counterstained with Hoechst 33342 (Invitrogen).
Senescence induction.
Oncogene-induced senescence (OIS) was performed by retroviral-mediated infection of primary human diploid fibroblasts (HDF) strain WI38 (population doubling 13) using pBABE-RASv12 and Phoenix packaging cells. Twenty four hours post-infection, cells were pharmacologically selected with 4 μg/ml puromycin (pBABE) for 2 days. Day 0 is considered when all non- infected cells were dead after pharmacological selection. Replicative senescent cells were produced by serial passaging of HDFs at normoxic oxygen conditions of 3% until replicative exhaustion. Cell populations were considered senescent when less than one population-doubling was completed per two weeks, EdU positivity was less than 1% and SA-b Gal positivity was greater than 70-80%.
Senescence analysis.
Senescence was assessed using several assays. For growth curves, cells were plated in triplicates at 2.0 x 104 per well in 12-well plates. Relative cell numbers were estimated at various time- points using a crystal violet incorporation assay and population doublings (PD) were calculated using the following equation: n=(loglOF - loglO1) x 3.32 (with n =PD, F =number of cells at the end of one passage, I=number of cells that were seeded at the beginning of one passage). For life-span studies, cells were sub-cultured when 70-80% confluent at 2 xl04/cm2. Proliferative capacity was assessed by labeling cells for 24 hours EdU. These cells were also co-stained for SA-β Gal. Tumor patient selection. Breast cancer patients were treated with 3 cycles of anthracycline and 3 cycles of docetaxel followed by surgery. As previously published (Chevallier et al. 1990), "Responders" exhibited a complete pathological response with only few residual cancer cells ( Chevallier score < 1). "Non Reponders" ( Chevallier score > 2) exhibited invasive primary tumors or lymph node metastases. Histology and immunochemistry. Samples from recovered tumors, mammary gland tissues and human breast adenocarcinoma were fixed with 4% PFA for 4h and then embedded into paraffin. Sections of 10 μιη were fixed and stained with haematoxylin and eosin (HE) according to standard protocols. For b-catenin, Lamp2 and p21WAF1 immunochemistry, antibodies used are described in "Cells, antibodies and reagents" section. Statistical analysis. To determine statistical significance, Student's i-test was used for calculation of P values.
RESULTS
Identification of tumor suppressive protein p53 as a repressor of cellular cannibalism. To identify the molecular basis of cancer-related cellular cannibalism, we determined the impact of the inactivation of 16 tumor suppressor proteins on cell internalization, the first step of cellular cannibalism. Among several cancer cell lines that spontaneously manifest cellular cannibalism (Figure 6A), we chose the colon carcinoma HCT1 16 cell line to determine cell internalization after inactivation of tumor suppressor proteins involved in cell cycle regulation (LKB1, PTEN, Rb and pl5INK4b), DNA repair (BRCA-1 and BRCA-2), DNA damage responses (ATM and ATR) and cell death regulation (FOXO-1, FOXO-2, FOXO-3, Beclin-1, Par-4, TP53, TP63 and TP73). After tumor suppressor knockdown, half of the cells were labeled with 5- chloromethylfluorescein diacetate (CMFDA, green fluorescence) and the other half with 5-(and- 6)-(((4-Chloromethyl)Benzoyl)Amino)Tetramethylrhodamine (CMTMR, red fluorescence), mixed together, and cultured for 24 hours (Figure 1 A and Figures 6B-Q). Subsequent, confocal microscopy revealed that depletion of TP53 resulted in a significantly enhanced frequency of cell-in-cell structures (Figures IB and 1C). Cell internalization was confirmed by immunostaining of membrane-bound β catenin revealing that one engulfing cell ("cannibal") can internalize more than one - up to six - cells ("targets") (Figure ID and Figure 7A). Neither CMFDA nor CMTMR did affect the frequency of cell-in-cell structures (not shown) or the propensity of cells to act as cannibals or targets (Figure IE), although they provided a better resolution for the detection of cellular cannibalism than classical immunohistochemistry staining (Figure 7B). Time-lapse microscopy of CMFDA/CMTMR-labelled, TP53-depleted cells demonstrated that cellular internalization occurred without morphological signs of apoptosis (such as membrane blebbing and formation of apoptotic bodies) (Figure 7C), in line with an absent activation of caspase-3 (Figure 7D). The internalization step was not related in its timing to symmetric or asymmetric mitoses of p53 depleted cells (Figure 7E). Pharmacological inactivation of TP53 with cyclic by pifithrin-a (Figure 1F,G), siRNA-
mediated depletion of TP53 (Figure 1F-I), or knockout of the Tp53 gene by homologous recombination (Figure 1F,G) induced cell-in-cell structures in HCT1 16 cells (Figure 1F,G), as well as in human primary fibroblasts (Figure 1H,I). Irrespective of the method of TP53 inactivation, inhibition of the serine threonine kinase ROCK by Y26732 (Overholtzer et al., 2007), prevented the generation of cell-in-cell structures (Figures 1F-I and Figures 2F-I), which however were not affected by the pan-caspase inhibitor Z-VAD-fmk (Figures 1F-I). Overall, our results identified a novel role for TP53 as a repressor of cellular cannibalism.
Δ133ρ53 is required for cellular cannibalism repression. Next, we used a battery of p53 mutants and isoforms to explore the mechanisms that govern the TP53-mediated regulation of cellular cannibalism. Wild type, full-length TP53, as well as a purely nuclear TP53 mutant (which lacks the nuclear export sequence, NES) were able to repress the formation of cell-in- cell structures, while a purely cytoplasmic TP53 mutant (which lacks a nuclear localization sequence, NLS) or two mutants that lack the transactivation activity of TP53 (due to frequent, cancer-associated mutations: R175H or R273H) were unable to repress the cannibalistic activity (Fig. 2A-D). All TP53 splice variants that differ in the start codon and hence in their N-terminus (ΤΡ53β, ΤΡ53γ, Δ40ΤΡ53 and Δ133ΤΡ53), including the shortest version (Δ133ΤΡ53), which lacks the amino-terminal transactivation and prolin-rich domains, were able to inhibit cannibalism (Fig. 2E,F). More importantly, selective depletion of Δ133ΤΡ53 with two distinct siRNAs that do not affect any other isoforms (Fig. 2G, (Fujita et al., 2009)) could induce cannibalism in several distinct cancer cell lines (HCT116, PANC) and primary human fibroblasts (Fig. 2H-L, Fig. 8A,B). Knockdown of all TP53 isoforms or that of Δ133ΤΡ53 alone similarly induced cannibalism.
In order to determine cellular consequences of Δ133ρ53 depletion, siRNA mediated knock down of Δ133ρ53 isoform from human colon HCT116 cells (Figure 2G-I), human pancreatic PANC813 cells (Figure 2 J) or from human normal WI39 fibroblasts (Figure 2K,L) was
performed during 48 hours. Then, control and depleted cells were labeled with either CMFDA or CMTMR, mixed together and cultured during 24 hours. Confocal microscopy analysis of these experiments revealed that reduction of Δ133ΤΡ53 expression induced ROCK-dependent and caspase-independent cannibalism in cancer cells (HCT116 and PANC) (Figure 21, J), but also in normal human fibroblasts (WI39) (Figure 2L). Next, we examined whether TP53 and Δ133ΤΡ53 act on cannibal cells or target cells. CMFDA-labeled (green) WT HCT116 cells (which express TP53) were co-cultured with CMTMR-labeled (red) cells that were manipulated for p53 expression: either WT cells transfected with s control siRNA, WT cells depleted from TP53 or Δ133ΤΡ53 only, or Tp53' cells. In this system, the absence of TP53 or Δ133ΤΡ53 alone enhanced the frequency of green-in-red cell structures, but not that of red-in-green figures (Fig. 2M). Hence, TP53 and Δ133ΤΡ53 act on the side of cannibal cells, not that of target cells, meaning that they increase the activity of cellular internalization on the side of the engulfing (not the engulfed) cell.
Extracellular ATP and P2Y2 purinergic receptors contribute to cannibalism. Stressed and dying cells can expose 'come get me' and 'eat me' signals or lose 'don't eat me' signals, thus facilitating their engulfment by neighboring cells (Grimsley and Ravichandran, 2003). The nucleotide ATP is released by stressed or dying cells and constitutes a potent chemotactic signal (Ravichandran, 2011) that can contribute to cell-to-cell contacts and fusions (Seror et al., 2011 ; Trautmann, 2009). Accordingly, tp53' cells (Figure 3A), as well as irradiated or CDDP treated cells (Figure 11B) and TP53 or Δ133ΤΡ53 depleted cells (Figure 11C) released ATP shortly after treatments (Figure 11B) or during coculture (Figure 3C and Figure 11C). These processes require ROCK signaling pathway (Figure 11B-D). Importantly, addition of recombinant apyrase, an enzyme that degrades ATP and ADP to AMP, reduced cellular internalization induced by the depletion of TP53 or Δ133ΤΡ53 in HCT1 16 (Figure 3B). Conversely, supplementation with ATP or UTP strongly enhanced the ROCK-dependent generation of cell- in-cell structures (Figure 3C,D), confirming that these nucleotides can stimulate cellular
cannibalism. Accordingly, the deletion or depletion of TP53 or Δ133ΤΡ53, respectively, enhanced the expression of the P2Y2 purinergic receptors (Fig. 3E,F), which are known to mediate ATP-dependent engulfment signals (Chekeni et al., 2010). In addition, 3% oxygen treated HDFs (Figure 1 IF), senescent (Figure 11G) and IR treated HEKns (Figure 11H) and CDDP or IR treated cells (Figure 111) enhanced the expression of the P2Y2 purinergic receptors. Knockdown of this particular purinergic receptor by two non- overlapping siRNAs reduced cellular cannibalism resulting from TP53 inhibition or depletion in HCT1 16 cells (Figure 3G), as well as in PANC813 cells (Figure 3H). Pharmacological inhibition of the upregulated purinergic P2Y2 receptor also reduced the cannibalism of human primary fibroblasts depleted from TP53 or Δ133ΤΡ53 (Fig. 3I-K) or stressed after replication (Figure 11 J). Considering that p53 acts on host cells to repress cellular cannibalism (Figure 2M), we decided to determine whether p53 inactivation controls P2Y2 activity on target cell side or/and host cell side. We revealed that the depletion of P2Y2 receptors on host cells reduced the ROCK-mediated phosphorylation of light chain 2 of myosine (data not shown) and cellular cannibalism (Figure UK) demonstrating that the ATP-driven activation of P2Y2 receptors on host cells favors cellular cannibalism.
Cellular invasion triggers senescence of cannibal cells. Confirming prior reports on entosis that describe the fatal destiny of engulfed cells (Overholtzer et al., Cell 2007), internalized cells were targeted to LAMP2+ lysosomal compartments for destruction, irrespective of the cell type that was analyzed (HCT116 or PANC813) after TP53 deletion or Δ133TP53 depletion (Fig. 9A- D), and cellular internalization was followed by nuclear degradation in an acidic compartment (Fig. 9E-G). In contrast cannibal cells conserved their viability. To investigate their long-term fate, we generated isogenic pairs of cancer cell lines (HCT116 WT, HCT116 Tp53' , PANC813) that stably expressed green or red fluorescent proteins in their nuclei (GFP-histone H2B and RFP-histone H2B fusion proteins). Mixtures of such cells were cocultured, optionally after depletion of Δ133ΤΡ53 to induce entosis, and cell-in-cell structures were seeded in microtiter
plates (with one single structure per well) and cultured for several days (Figure 4A and Figure ΙΟΑ,Β). In contrast to single control cells, cell-in-cell structured formed from CT116 WT or HCT116 Tp5$'- cells that were depleted from Δ133ΤΡ53 were unable to proliferate (and hence to increase their cell number), and demonstrated an increase in cell size and nuclear size, corresponding to an increase in ploidy (Figure 4B,C). This correlated with reduced incorporation of the DNA precursor 5-ethynyl-2'-deoxyuridine (EdU), a thymidine analogue (Figure 4C,D), increased staining of the nuclei from cannibal (but not target) cells with antibody recognizing phosphorylated histone H2AX (γΗ2ΑΧ DNA damage foci) (Figure 4E,F) or p53BPl (which also labels DNA damage foci (Lukas et al., 2011)) (Figure 4E,F), and cytoplasmic senescence associated β-galactosidase (SA-P-Gal) activity (Figure 4G,H), as well as expression of the cycline-dependent kinase inhibitory protein p21WAF1 (Figure 4I-K). siRNA- mediated depletion of p21WAF1 reduced sings of senescence including SA-P-Gal staining (Figure 4L-N) and allowed the cells to resume EdU incorporation (data not shown). According to the word entosis that defined a non-apoptotic cell death mechanism occuring after cell internalization, we termed this new modality of senescence induction, entescence.
Altogether, these results provide evidence for a link between Δ133ρ53 or p53 depletion, senescence and cellular cannibalism.
Senescence favors cannibalism. Oncogenic stress-induced senescence triggered by transducing primary human WI38 fibroblasts with Rasv12 (Figure 5A-C) led to an increase in P2Y2 expression (Fig. 5 A), paralleling an increase in pi 6 and a loss of Rb expression, two phenomena that are known to be associated with senescence (Lowe et al., Nature 2004). In addition, Rasv12 mediated retroviral transduction resulted in an increase in the frequency of cannibalistic events, allowing the Rasvl2-expressing fibroblasts to engulf HCT116 cells or normal non-senescent fibroblasts (Fig. 5B,C), through a process that depended on ROCK but not on caspases (Fig. 5C). Replicative stress induced by replicative exhaustion of HDFs at 3% normoxic oxygen
conditions of upregulated P2Y2 (Fig. 5D) and stimulated cannibalism (Fig. 5E). Inhibition of P2Y2 receptors reduced the frequency of cannibalistic events induced by Rasv12 (Fig. 5F). In addition, replicative senescence of human primary epidermal keratinocyte (HEKn) (Rivetti di Val Cervo et al., PNAS 2012) led to the induction of P2Y2 protein (Fig. 5G) and elevated cannibalism (Fig. 5H) requiring ROCK and P2Y2 (Fig. 51). Prevention of cannibalism with inhibitors of ROCK or P2Y2 also reduced the frequency of senescent, SA-P-Gal-positive cells accumulating in aging cultures (Fig. 5J). These results support the ability of senescent cells to manifest a cannibalistic behavior and to engulf neighboring cells.
Entescence contributes to cellular senescence through P2Y2 activation.
To further characterize the role of cellular cannibalism during senescence induction, we evaluated the impact of purinergic P2Y2 receptor activity on entescence and on cell autonomous senescence and observed that the pharmacological inhibition of purinergic P2Y2 receptor with kaempferol strongly reduced senescence observed during replicative stress of HEKns (Figure 12A) or after treatment of HCT116 cells with IR or with MTX (Figure 12B) as revealed by the reduction of the frequency of senescent, SA-P-Gal-positive cannibal cells (Figures 12A,B). Then, we evaluated the contribution of P2Y2 signaling pathways on p53 depletion induced entescence and revealed that P2Y2 depletion reduced significantly entescence detected after p53 deletion or depletion (Figure 12C). These results were also confirmed after the depletion of the senescence regulator Δ133ρ53. As we previously described the depletion of Δ133ρ53 isoform from human colon HCT1 16 cells triggers cellular cannibalism (Figures 3I,J). Time lapse imaging of Δ133ρ53 depleted HCT1 16 cells that stably expressed GFP-histone H2B and RFP- histone H2B fusion proteins highlighted that once internalized target cells are degraded within less than one hour and then, cannibal cells increased their size and nuclear size (Figure 12D). This process is associated with an increased staining of the nuclei from cannibal cells with
antibodies recognizing γΗ2ΑΧ DNA damage foci (Figures 12E,G) or p21 (Figures 12E,H), and the induction of SA-P-Gal activity (Figures 12F,I) demonstrating that Δ133ρ53 depleted HCT116 cells undergo entescence. Depletion of p21 by two siRNA revealed reduced entescence (Figure 4N), but also entescence associated cannibalism (Figure 40) highlighting that senescent cells and entescent cells are both able to internalize neighboring cells. We also demonstrated that P2Y2 depletion reduced specifically the frequency of cannibal cells showing for γΗ2ΑΧ positive nuclear foci (Figure 5G), p21 expression (Figure 5H) and SA-P-Gal activity (Figure 51) revealing that the purinergic P2Y2 receptor modulate cellular senescence by controlling the engulfment of neighboring cells. Taken together, these data demonstrated that entescence contributes to the establishment of cellular senescence.
Detection of entescence in vivo
Despite cell-in-cell cytological feature of cellular cannibalism has been detected in numerous human cancer, role of cellular cannibalism during oncogenesis was only recently studied (Overholtzer et al., Nature reviews Molecular cell biology 2008; Cano et al., EMBO Mol. Med. 2012) and depending on tumor microenvironment, could either contribute to tumor suppression through entosis induction {Overholtzer et al., Cell 2007; Cano et al., EMBO Mol. Med. 2012), but could also increase genomic instability of cannibal cells by modulating cytokinesis (Krajcovic et al., Nat Cell Biol. 2011). To validate our vitro based hypothesis demonstrating that cellular cannibalism is associated with senescence, we decided to determine whether human Spitz tumors that contain many senescent cells also show presence of cannibal cells. We analyzed human Spitz tumors and human aggressive melanomas using HE and immunofluorescence stainings and detected an increase of cannibal cells in Spitz tumor biopsies, as compared to aggressive melanoma (data not shown). In comparison to malignant melanomas which are known to be deleted or mutated
for pi 6 a (Kamb et al, Nat Genet 1994), the vast majority of these begnin tumors contain senescent cells highlighting that cellular cannibalism is also associated with senescence in vivo. In addition, these results also suggest that induction of cellular cannibalism would determine the long-term survival of patients and animals to chemotherapy {Schmitt et al. Nature reviews Cancer, 2003; Lowe et al., Nature 2004). To confirm this hypothesis, we determined whether cannibal cells detected on human breast adenocarcinoma could undergo senescence after neo-adjuvant treatment. First, we analyzed normal human breast and primary breast carcinoma biopsies using the previous experimental strategy and found that all biopsies revealed feature of cellular cannibalism (Figure 13A and Figure 13B). The frequency of cell engulfment was 10 fold higher in primary breast carcinomas (mean+/- SD=, n=30) than in normal tissues (mean+/-SD=, n=10) (Figure 13C). To determine whether cellular cannibalism correlates with disease progression, we analyzed 10 biopsies of patients diagnosed with a grade 1 , with a grade 2 or a grade 3 of breast carcinomas and observed that the frequency of cannibal cells significantly increased with the histological tumor grade (Figure 13D). To precise the impact of cellular cannibalism on breast cancer progression, we wondered to know whether of neo-adjuvant treatments could increase cellular cannibalism and senescence of cannibal cells. We examined 30 biopsies of untreated breast carcinomas and 15 neo-adjuvant treated breast carcinomas for cell engulfment and we found no changes in the frequency of cannibal cells, but we observed cannibal cells with an increase in cell and nuclear sizes in neo-adjuvant treated tumor biopsies as compared to untreated (Figure 13E a-c). Then, we stained sections from 30 untreated tumors and 15 treated tumors with for β-catenin and p21WAF1 antibodies (Figure 13F) and observed in half of neo-adjuvant treated tumors that single and cannibal cells are positive for p21 WAF1+ (Figure 13G), confirming our previous results on Spitz tumors that cellular cannibalism and senescence are two interlinked processes that can also be detected in patients after neoadjuvant treatments in vivo. Considering that breast carcinomas represent a heterogeneous
group of tumors with different morphological and biological features, behavior and response to therapy, we compared the impact of cellular cannibalism and senescence on tumor and disease progressions between to distinct types of breast tumor that were treated with neoadjuvant treatment. First, we determined the frequency of cellular cannibalism on breast tumor biopsies obtained from 26 patients with locally advanced breast cancers and observed that the efficiency of neo-adjuvant chemotherapy is associated with induction of cellular cannibalism (Figure 14H). Cannibal cells detected in responder patients revealed evidences of cellular senescence (such as increase of their cellular and nuclear sizes, expression of p21WAF1 and absence of Ki67 staining). In contrast, biopsies from non-responder patients revealed a strong reduction of cellular cannibalism and did not present signs of entescence or cellular cannibalism associated to senescence. More important, we found that the detection of cellular cannibalism is associated with an increase of disease free and overall survivals of treated patients (Figure 14B and Figure 14C) suggesting that the detection of cellular cannibalism (and more precisely senescence of cannibal cells) on biopsies obtained from breast tumors strongly predict response to neo-adjuvant treatment. Then, we determined whether the detection of cellular cannibalism in triple negative breast cancer tumors (TNBC) that are more aggressive tumors could also predict the efficiency of neoadjuvant treatment. We evaluated the frequency of cannibal cells on 71 TNBC biopsies obtained after neo-adjuvant treatment and revealed that the detection of cellular cannibalism also predict the efficiency of neo-adjuvant treatment on TNBC patients, but with great interest in these tumors that harbor p53 mutation and don't undergo senescence, the accumulation of cellular cannibalism is associated with the absence of response to neoadjuvant treatment (Figure 14D) and a strong reduction of disease free survival and overall survival of treated patients (Figure 14E and Figure 14F). These results confirmed those obtained in Figure 15 demonstrating that p53 mutations repress entescence and lead to the accumulation of cannibal polyploidy cells that are able to divide and restart proliferation.
Overall, these data obtained in vivo confirm that entescence or/and senescence associated to cellular cannibalism also occur in patients and their detections could help for the determination of disease outcomes and for the prediction of chemo- and radiotherapy efficiency.
DISCUSSION
Here, we show that pharmacological and genetic inhibitions of TP53 or Δ133ΤΡ53 initiate cellular cannibalism by inducing ATP release and P2Y2 activation. After internalizing target cells, cannibal cells become senescent through p21WAF1 induction. Once senescent, cannibal cells can also internalize other lived neighboring cells. These findings provide the first demonstration that cellular cannibalism may modulate tumor growth despite TP53 or Δ133ΤΡ53 expression is reduced.
Although signaling pathways elicited by TP53 inactivation were extensively investigated, we show that ATP is released into the extracellular milieu during cell interactions between TP53 deficient cells or between Δ133ΤΡ53 depleted cells (Figure 3A and data not shown) and that this extracellular ATP is required for cell internalization (Figure 3B-D). Release of ATP by cells occurs through multiple mechanisms that may activate membrane channels (including connexin and pannexin hemichannels) or induce exocytic or autophagic mechanisms (Corriden and Insel, 2010). Autophagy also known as "self-eating" is a cellular response to multiple stresses that TP53 was recently identified as regulator of autophagy. Deletion, depletion and inhibition of TP53 can induce autophagy in human, mouse and nematode cells (Tasdemir et al., 2008), but autophagy is also required for ATP release from dying tumor cells during chemotherapy cells and contributes to immunogenicity. In this context, we postulated that release of ATP that we detected during culture of TP53_/" cells (Figure 3A) or Δ133ΤΡ53 depleted cells (data not
shown) could be initiated by autophagy. Furhter characterization of mechanisms that are required for ATP release will determine the role of autophagy in cellular cannibalism. During entosis, autophagy machinery was involved in the degradation of internalized cell (Florey et al., Nat Cell Biol. 2011; Florey and Overholtzer, Trends Cell Biol. 2012), but impact of autophagy on cell-in-cell structure formation remains to be investigated.
Once release, extracellular ATP can exert a wide range of cellular effects by activating plasma membrane bound receptors such as ionotropic purinergic P2X receptors and metabolotropic P2Y receptors (Burnstock, Cell Mol Life Sci. 2007). In this study, we revealed that TP53 or Δ133ΤΡ3 knockdowns increase expression of heterotrimeric guanine nucleotide binding protein (protein G) coupled P2Y2 receptors in normal and in cancer (Figure 3). More important, P2Y2 depletion impairs cell engulfment and reduces drastically reduces frequencies of cell-in-cell structures detected after TP53 or Δ133ΤΡ53 inactivation, demonstrating that P2Y2 participates in the engulfment of neighboring cells by cannibal cells. Purinergic P2Y2 receptor contributes to actine cytoskeleton rearrangement that is required for cell interactions and cell fusion (Paoletti et al., PNAS 2012; Seror et al., 2011) and increases mobility of cells through activation of Rho and formation of Rho dependent stress fibers (Bagchi et al., 2005; Chen et al., 2006; Liao et al., 2007; Liu et al., 2004). Indeed, depletion of TP53 changes the morphology and the polarity of cells (Gadea et al., 2007; Gadea et al., 2002; Guo et al., 2003), but also increases mobility in numerous cell types (including keratinocytes and colon cancer HCT1 16 cells) (Lefort et al., 2007; Sablina et al., 2003). Evidences that signaling pathways modulating cell migration and chemotaxis are influenced by TP53 have been also produced (Gadea et al., 2007; Gadea et al., 2002; Guo and Zheng, 2004; Lefort et al., 2007; Roger et al., 2006; Xia and Land, 2007), demonstrating that TP53 loss drives increased activity of Rho/ROCK axis to promote cell mobility and invasion during tumor progression. Additional experiments have to be developed to determine the link between extracellular ATP and purinergic P2Y2 activation, and Rho/ROCK dependent signaling pathways during cellular cannibalism. Our results suggest that
after TP53 or Δ133ΤΡ53 depletion, extracellular ATP and purinergic P2Y2 receptors activation may enhance mobility of cannibal cells and favor engulfitnent of neighboring cells.
Cellular cannibalism was initially described as non apoptotic cell death that is provoked by loss of attachment to extracellular matrix and led to destruction of internalized cells through lysosomal degradation. This atypical cell death modality was defined as entosis and was proposed as a new tumor suppressor mechanism to control tumor growth and metastatic dissemination (Overholtzer et al., 2007). More recently, studies on cellular cannibalism demonstrated that internalizing cells (that we previously defined as cannibal cells) cause a cytokinesis failure of cannibal cells by disrupting the formation of the contractile ring during cannibal cell division. Hence, cellular cannibalism initiates a non-genetic mechanism of cytokinesis failure and increase genomic instability by generating aneuploidy cells (Krajcovic et al., 2011; Krajcovic and Overholtzer, 2012). Here we demonstrated that cell engulfitnent induces hyperploidy and senescence of cannibal cells when TP53 or Δ133ΤΡ3 is reduced. Senescence is a stable cell cycle arrest that is induced at the end of the cellular lifespan or in response to different stresses (such as replicative or oxidative stresses, DNA damage, chemotherapeutic drugs). No specific markers for senescence have been identified, but senescent status of cells is determined by detecting an irreversible growth arrest, the expression of the cytoplasmic senescence associated β-galactosidase (SA-pGal), the re-expression of cell cycle inhibitors (such as pl6INK4a or p21WAF1), the secretion of numerous growth factors, cytokines and proteases; and by the presence of nuclear foci that contain DNA damage response (DDR) proteins or heterochromatin. We found that cannibal cells showed an irreversible growth arrest, expressed cytoplasmic senescence associated β-galactosidase (SA-P-Gal) activity and the cycline-dependent kinase inhibitory protein p21WAF1. We also detected DDR foci in the nuclei of cannibal cells demonstrating that in absence of TP53 or Δ133ΤΡ53, cancer cells become senescent after cell engulfitnent. Although transcriptional activity of TP53 is frequently required for the induction of senescence, we unrevealed that senescence induction occurs in absence of
TP53 or its Δ133ΤΡ53. Our results were in accord with previously published reports demonstrating that cellular senescence may be induced in melanoma in absence of TP53 (Ha et al., 2007; Ha et al., 2008) or by ARF independent TP53 signaling pathways (Lin et al., 2010). Recently, decrease of Δ133ΤΡ53 and overexpression of ΤΡ53β participate to replicative senescence, but not oncogene induced senescence (Fujita et al., 2009). In addition, we also detected on cannibal cells, DNA damage responses (as revealed by nuclear foci containing γ- H2AX and 53BP1) and p21WAF1 overexpression, two cellular processes that are required for replicative or oncogenic senescence. Inhibition of p21WAF1 expression reduced senescence of cannibal cells depleted for TP53 or for Δ133ΤΡ53, suggesting that p21WAF1 overexpression is induced through TP53-dependent or independent mechanisms. Cellular senescence is a crucial barrier to tumor progression in vivo (Kuilman et al., 2010). Understanding molecular and cellular basis of senescence represent a crucial step to fight cancer and develop therapeutic strategies (such as pro-senescent therapy (Nardella et al., 2011)) to reduce tumor growth and metastatic dissemination. Here, we highlighted a new mechanism for tumor suppression that could be enhanced for therapeutic benefits when TP53 signaling pathways are impaired.
BIBLIOGRAPHIC REFERENCES
Bagchi S, Liao Z, Gonzalez FA, Chorna NE, Seye CI, Weisman GA, Erb L. The P2Y2 nucleotide receptor interacts with alphav integrins to activate Go and induce cell migration. J Biol Chem. 2005 Nov 25;280(47):39050-7.
Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell. 2006 Jul 14;126(l): 107-20.
Bourdon JC. p53 and its isoforms in cancer. Br J Cancer. 2007 Aug 6;97(3):277-82.
Burnstock G. Purine and pyrimidine receptors. Cell Mol Life Sci. 2007 Jun;64(12):1471-83. Cano CE, Sandi MJ, Hamidi T, Calvo EL, Turrini O, Bartholin L, Loncle C, Secq V, Garcia S, Lomberk G, Kroemer G, Urrutia R, lovanna JL. Homotypic cell cannibalism, a cell-death process regulated by the nuclear protein 1, opposes to metastasis in pancreatic cancer. EMBO Mol Med. 2012 Sep;4(9):964-79
Cartier-Michaud A, Malo M, Charriere-Bertrand C, Gadea G, Anguille C, Supiramaniam A, Lesne A, Delaplace F, Hutzler G, Roux P, Lawrence DA, Barlovatz-Meimon G.Matrix-bound PAI-1 supports cell blebbing via RhoA/ROCKl signaling. PLoS One. 2012;7(2) :e32204.
Faraaz B. Chekeni, Michael R. Elliott, Joanna K. Sandilos, Scott F. Walk, Jason M. Kinchen, Eduardo R. Lazarowski, Allison J. Armstrong, Silvia Penuela, Dale W. Laird, Guy S. Salvesen, Brant E. Isakson, Douglas A. Bayliss, Kodi S. Ravichandran Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature. 2010 October 14; 467(7317): 863-867
Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, Nizet V, Insel PA, Junger WG. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science. 2006 Dec 15;314(5806): 1792-5. B. Chevallier, V. Mosseri, J. P. Dauce, P. Bastit, J. P. Julien, B. Asselain A prognostic score in histological node negative breast cancer. Br J Cancer. 1990 March; 61(3): 436-440.
Jean-Philippe Coppe, Christopher K Patil, Francis Rodier, Yu Sun, Denise P Munoz, Joshua Goldstein, Peter S Nelson, Pierre- Yves Desprez, Judith Campisi Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor PLoS Biol. 2008 December; 6(12): e301.
Ross Corriden, Paul A. Insel.Basal Release of ATP: An Autocrine-Paracrine Mechanism for Cell Regulation. Sci Signal. 2010 January 12; 3(104): rel .
Demidenko, Z.N. et al. Proceedings of the National Academy of Sciences of the United States of America 107, 9660-9664 (2010).
Zoya N. Demidenko, Lioubov G. Korotchkina, Andrei V. Gudkov, Mikhail V. Blagosklonny. Paradoxical suppression of cellular senescence by p53. Proc Natl Acad Sci U S A. 2010 May 25; 107(21): 9660-9664. Fasanaro et al, Pharmacol. Ther. 2010; 125(1):92-104
Oliver Florey, Sung Eun Kim, Cynthia P. Sandoval, Cole M. Haynes, Michael Overholtzer. Autophagy machinery mediates macroendocytic processing and entotic cell death by targeting single membranes.Nat Cell Biol. 2011 October 16; 13(11): 1335-1343.
Oliver Florey, Michael Overholtzer.Autophagy proteins in macroendocytic engulfment Trends Cell Biol.2012 July; 22(7): 374-380.
Kaori Fujita, Abdul M. Mondal, Izumi Horikawa, Giang H. Nguyen, Kensuke Kumamoto, Jane J. Sohn, Elise D. Bowman, Ewy A. Mathe, Aaron J. Schetter, Sharon R. Pine, Helen Ji, Borivoj Vojtesek, Jean-Christophe Bourdon, David P. Lane, Curtis C. Harris. p53 isoforms, Δ133ρ53 and ρ53β, are endogenous regulators of replicative cellular senescence. Nat Cell Biol. 2009 September; 11(9): 1135-1142.
Gilles Gadea, Marion de Toledo, Christelle Anguille, Pierre Roux. Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J Cell Biol. 2007 July 2; 178(1): 23-30.
Gadea G, Lapasset L, Gauthier-Rouviere C, Roux P. Regulation of Cdc42-mediated morphological effects: a novel function for p53. EMBO J. 2002 May 15;21(10):2373-82.
Gonzalez-Pastor JE, Hobbs EC, Losick R. Cannibalism by sporulating bacteria. Science. 2003 Jul 25;301(5632):510-3.
Gottlieb E, Vousden KH. p53 regulation of metabolic pathways. Cold Spring Harb Perspect Biol. 2010 Apr;2(4):a001040. Grimsley C, Ravichandran KS. Cues for apoptotic cell engulfment: eat-me, don't eat-me and come-get-me signals. Trends Cell Biol. 2003 Dec;13(12):648-56.
Guiral S, Mitchell TJ, Martin B, Claverys JP. Competence-programmed predation of noncompetent cells in the human pathogen Streptococcus pneumoniae: genetic requirements. Proc Natl Acad Sci U S A. 2005 Jun 14;102(24):8710-5. Guo F, Gao Y, Wang L, Zheng Y.pl9Arf-p53 tumor suppressor pathway regulates cell motility by suppression of phosphoinositide 3-kinase and Racl GTPase activities.Biol Chem. 2003 Apr 18;278(16):14414-9.
Ha L, Ichikawa T, Anver M, Dickins R, Lowe S, Sharpless NE, Krimpenfort P, Depinho RA, Bennett DC, Sviderskaya EV, Merlino G. ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence. Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):10968- 73.
Ha L, Merlino G, Sviderskaya EV. Melanomagenesis: overcoming the barrier of melanocyte senescence. Cell Cycle. 2008 Jul l ;7(13):1944-8.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000 Jan 7;100(l):57-70.
Hanahan D, Weinberg RA.Hallmarks of cancer: the next generation. Cell. 2011 Mar 4;144(5):646-74.
Janicke RU, Sohn D, Schulze-Osthoff K. The dark side of a tumor suppressor: anti-apoptotic p53. Cell Death Differ. 2008 Jun;15(6):959-76.
Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrara P, McKeon F, Caput D. Monoallelically expressed gene related to p53 at lp36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997 Aug 22;90(4):809-19.
Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, et al. Analysis of the pi 6 gene (CDK 2) as a candidate for the
chromosome 9p melanoma susceptibility locus. Nat Genet. 1994 Sep;8(l):23-6.
Krajcovic M, Johnson NB, Sun Q, Normand G, Hoover N, Yao E, Richardson AL, King RW, Cibas ES, Schnitt SJ, Brugge JS, Overholtzer M. A non-genetic route to aneuploidy in human cancers. Nat Cell Biol. 2011 Mar;13(3):324-30.
Krajcovic M, Overholtzer M. Mechanisms of ploidy increase in human cancers: a new role for cell cannibalism. Cancer Res. 2012 Apr 1 ;72(7): 1596-601.
Khoury MP, Bourdon JC.The isoforms of the p53 protein. Cold Spring Harb Perspect Biol. 2010 Mar;2(3):a000927
Kuilman T, Michaloglou C, Mooi WJ, Peeper DS. The essence of senescence. Genes Dev. 2010 Nov 15;24(22):2463-79. Lefort K, Mandinova A, Ostano P, Kolev V, Calpini V, Kolfschoten I, Devgan V, Lieb J, Raffoul W, Hohl D, Neel V, Garlick J, Chiorino G, Dotto GP. Notchl is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCKl/2 and MRCKalpha kinases. Genes Dev. 2007 Mar l ;21(5):562-77.
Li W, Baker NE.Engulfment is required for cell competition. Cell. 2007 Jun 15;129(6):1215-25. Li C. et al, AAPSJ, 2009; 1 1(4):747-757
Liao Z, Seye CI, Weisman GA, Erb L. The P2Y2 nucleotide receptor requires interaction with alpha v integrins to access and activate G12. J Cell Sci. 2007 May l ;120(Pt 9): 1654-62.
Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, Cordon-Cardo C, Teruya-Feldstein J, Pandolfi PP. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature. 2010 Mar 18;464(7287):374-9. Liu J, Liao Z, Camden J, Griffin KD, Garrad RC, Santiago-Perez LI, Gonzalez FA, Seye CI, Weisman GA, Erb L. Src homology 3 binding sites in the P2Y2 nucleotide receptor interact with Src and regulate activities of Src, proline-rich tyrosine kinase 2, and growth factor receptors. J Biol Chem. 2004 Feb 27;279(9):8212-8.
Lowe, S.W., Cepero, E. and Evan, G.Intrinsic tumour suppression. Nature 432, 307-315 (2004).
Lukas C, Savic V, Bekker- Jensen S, Doil C, Neumann B, Pedersen RS, Grofte M, Chan KL, Hickson ID, Bartek J, Lukas J. 53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress.Nat Cell Biol. 201 1 Mar;13(3):243-53. doi:
Matsuura F, Hirano K, Ikegami C, Sandoval JC, Oku H, Yuasa-Kawase M, Tsubakio- Yamamoto K, Koseki M, Masuda D, Tsujii K, Ishigami M, Nishida M, Shimomura I, Hori M, Yamashita S. Senescent phenotypes of skin fibroblasts from patients with Tangier disease. Biochem Biophys Res Commun. 2007 Jun l ;357(2):493-8. Epub 2007 Apr 9.
Overholtzer, M., and Brugge, J.S.The cell biology of cell-in-cell structures. Nature reviews Molecular cell biology 9, 796-809. (2008)
Overholtzer, M., Mailleux, A.A., Mouneimne, G., Normand, G., Schnitt, S.J., King, R.W., Cibas, E.S., and Brugge, J.S. (2007). A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion. Cell 131, 966-979.
Paoletti, A., Raza, S.Q., Voisin, L., Law, F., Pipoli de Fonseca, J., Caillet, M., Kroemer, G., and Rivetti di Val Cervo, P., Lena, A.M., Nicoloso, M., Rossi, S., Mancini, M., Zhou, H., Saintigny, G.,
Dellambra, E., Odorisio, T., Mahe, C, et al. (2012). p63-microRNA feedback in keratinocyte senescence. Proceedings of the National Academy of Sciences of the United States of America 109, 1133-1138. Parr CE. et al, 1994, PNAS 91 (8):3275-9
Rivetti di Val Cervo et al, Proc Natl Acad Sci U S A. 2012 Jan 24; 109(4): 1 133-8
Roger, L., Gadea, G., and Roux, P. (2006). Control of cell migration: a tumour suppressor function for p53 Biology of the cell / under the auspices of the European Cell Biology Organization 98, 141 - 152.
Sablina, A.A., Budanov, A.V., Ilyinskaya, G.V., Agapova, L.S., Kravchenko, J.E., and Chumakov, P.M. (2005). The antioxidant function of the p53 tumor suppressor. Nature medicine 77, 1306-1313.
Sablina, A.A., Chumakov, P.M., and Kopnin, B.P. (2003). Tumor suppressor p53 and its homologue p73 alpha affect cell migration. The Journal of biological chemistry 278, 27362- 27371.
Schmitt, C.A. (2003). Senescence, apoptosis and therapy-cutting the lifelines of cancer. Nature reviews Cancer 3, 286-295.
Seror, C, Melki, M.T., Subra, F., Raza, S.Q., Bras, M., Saidi, H., Nardacci, R., Voisin, L., Paoletti, A.,
Law, F., et al. (2011). Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection. The Journal of experimental medicine 208, 1823-1834.
Tasdemir, E., Maiuri, M.C., Galluzzi, L., Vitale, I., Djavaheri-Mergny, M., DAmelio, M., Criollo, A., Teodoro, J.G., Evans, S.K., and Green, M.R. (2007). Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. J Mol Med (Berl) 85, 1175- 1186.
Tolstonog, G.V., and Deppert, W. (2010). Metabolic sensing by p53: keeping the balance between life and death. Proceedings of the National Academy of Sciences of the United States of America 707, 13193-13194.
Vogelstein, B., Lane, D., and Levine, A.J. (2000). Surfing the p53 network. Nature 408, 307- 310.
Vousden, K.H., and Lane, D.P. (2007). p53 in health and disease. Nature reviews Molecular cell biology 5, 275-283.
Vousden, K.H., and Lu, X. (2002). Live or let die: the cell's response to p53. Nature reviews Cancer 2, 594-604. Vousden, K.H., and Prives, C. (2009). Blinded by the Light: The Growing Complexity of p53. Cell 137, 413-431.
Waddell, D.R., and Duffy, K.T. (1986). Breakdown of self/nonself recognition in cannibalistic strains of the predatory slime mold, Dictyostelium caveatum. The Journal of cell biology 702, 298-305
Xia, M., and Land, H. (2007). Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility. Nature structural & molecular biology 14, 215-223.
Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, Andrews NC, Caput D, McKeon F. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities.Mol Cell. 1998 Sep;2(3):305-16. Yonish-Rouach, E., Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. (1991). Wild- type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352, 345-347.
Claims
1. A method of identifying a compound that modulates cellular cannibalism, comprising the steps of:
(a) adding a compound to a cell culture in vitro,
(b) measuring in said culture the expression level of a protein selected from the group consisting of p53 and N-terminal isoforms of p53 that lack the N-terminal transactivating domain, such as Δ40ΤΡ53 and Δ133ΤΡ53;
wherein a compound that represses cellular cannibalism is identified by a normal expression or an increase in the expression levels of p53 or said isoforms, as compared to control levels.
2. A method of identifying a compound that modulates cellular cannibalism, comprising the steps of:
(a) adding a compound to a cell culture in vitro,
(b) measuring in said culture the expression level of a protein selected from the group consisting of ρ53β and ρ53γ,
wherein a compound that represses cellular cannibalism is identified by a decrease in the expression levels of ρ53β and/or ρ53γ, as compared to control levels.
3. A method of identifying a compound that modulates cellular cannibalism, comprising the steps of:
(a) adding a compound to a cell culture in vitro,
(b) measuring in said culture the extracellular amount of ATP,
wherein a compound that represses cellular cannibalism is identified by a decrease in the extracellular amount of ATP, as compared to control levels.
4. A method of identifying a compound that modulates cellular cannibalism, comprising the steps of:
(a) adding a compound to a cell culture in vitro,
(b) measuring in said culture the expression level or the activity of the purinergic P2Y2 receptor,
wherein a compound that represses cellular cannibalism is identified by a decrease in the expression level or the activity of the purinergic P2Y2 receptor, as compared to control levels.
5. An in vitro method for detecting cannibalism behavior of a cell, comprising the step of measuring in said cell :
• the expression level of a protein selected from the group consisting of p53 and N-terminal iso forms of p53 that lack the N-terminal transactivating domain, such as Δ40ΤΡ53 and Δ133ΤΡ53, and/or
• the expression level or the activity of the purinergic P2Y2 receptor, and/or
• secreted extracellular ATP, and/or
• the expression level of a protein selected from the group consisting of ρ53β and ρ53γ,
wherein the said cell has cannibalism activity if the expression levels of p53 or said Δ40ΤΡ53 and Δ133ΤΡ53 isoforms is low, and/or if secretion of extracellular ATP is
high, and/or if the expression level or the activity of the purinergic P2Y2 receptor is high, and/or if the expression level of ρ53β or ρ53γ is high, as compared to control levels.
The method according to any one of claims 1 to 5, further comprising the step of measuring at least one senescence marker, for example selected from the group consisting of: p21WAF1, Ki67, pi 6, Rb, or SA-P-Gal.
The method according to any one of claims 1 to 6, wherein measuring expression levels of a protein comprises measuring mRNA levels of this protein.
A method of inducing cellular cannibalism in a cell in vitro, comprising inhibiting in said cell the expression of p53 or of an N-terminal isoform of TP53 selected from Δ133ΤΡ53 and Δ40ΤΡ53.
9. The method according to claim 8, wherein said inhibition is achieved by using a miRNA or a siRNA.
The method according to claim 8 or 9, wherein said p53 expression inhibition is achieved by using the siRNA of SEQ ID: 17 (siRNA-1 : 5'GACUCCAGUGGUAAUCUAC 3') or SEQ ID NO: 18 (siRNA-2 :5'GCAUGAACCGGAGGCCCAU 3')·
The method according to claim 8 or 9, wherein said Δ133ΤΡ53 expression inhibition is achieved by using the siRNA of SEQ ID NO: 19 (siRNA-1 : 5'UGUUCACUUGUGCCCUGACUUUCAA3') or SEQ ID NO:20 (siRNA-2 : 5 'CUUGUGCCCUGACUUUCAA3 ')·
A method of inhibiting cellular cannibalism in a cell in vitro, comprising inhibiting in said cell the expression of ρ53β or ρ53γ, or of the purinergic P2Y2 receptor, or inhibiting the secretion of extracellular ATP.
The method according to claim 12, wherein said inhibition is achieved by using a miRNA or a siRNA.
An in vitro method of determining an increase in the propensity of cells to be a target of cellular cannibalism, comprising measuring in the cell a marker selected from the group consisting of: (a) increased extracellular release of ATP, (b) decreased p53 expression, (c) decreased Δ133ΤΡ53 expression, (d) increased expression of ρ53β or ρ53γ, (e) increased expression or activity of P2Y2 purigenic receptors.
A siRNA inhibiting the expression of Δ133ΤΡ53, for use for inducing cell cannibalism and senescence in tumor cells.
The siRNA of claim 15, for use for treating cancer.
The siRNA of claim 15 and 16, having the sequence SEQ ID NO: 19 (siRNA-1 5'UGUUCACUUGUGCCCUGACUUUCAA3') or SEQ ID NO:20 (siRNA-2 5 'CUUGUGCCCUGACUUUCAA3 ')·
A miRNA inhibiting the expression of Δ133ΤΡ53, for use for inducing cannibalism and senescence in tumor cells.
The miRNA of claim 18, for use for treating cancer.
A siRNA inhibiting the expression of p53, for use for inducing cell cannibalism and senescence in tumor cells.
The siRNA of claim 20, for use for treating cancer.
The siRNA of claim 20 or 21, having the sequence SEQ ID NO: 17 (siRNA- 1 5'-GACUCCAGUGGUAAUCUAC-3') or SEQ ID NO: 18 (siRNA-2: 5' GCAUGAACCGGAGGCCCAU-3 ').
An in vitro method of determining the prognosis of patient suffering from cancer, comprising the step of measuring the expression levels of p53 or of one of its iso forms Δ133ΤΡ53, ΤΡ53β, ΤΡ53γ, or Δ40ΤΡ53, or the expression level or the activity of the purinergic P2Y2 receptor, and the expression level of a senescence marker such as p21WAF1, Ki67, pi 6, Rb, or SA-P-Gal, in tumor cells isolated from the patient.
An in vitro method of determining the susceptibility of tumor cells to an anticancer treatment, comprising the step of detecting simultaneously the cannibal and senescent behavior of the said cells by using the method of claim 6, wherein, if the said tumor cells have high cannibal and senescent activities, then the said tumor cells will be sensitive to the said anti-cancer treatment.
The method of claim 24, wherein said cancer is chosen in the group consisting of : melanoma, spitz tumors, prostate cancer, colon carcinoma, and liver carcinoma, breast cancer, lung cancer, cervical cancer, and bone cancer.
An in vitro method of determining the resistance of tumor cells to an anticancer treatment, comprising the step of detecting simultaneously the cannibal and senescent behavior of the said cells by using the method of claim 6, wherein, if the said tumor cells treated with said anti-cancer treatment have cannibal activity but low or no senescent activity, then the said tumor cells will be resistant to the said anti-cancer treatment.
The method of claim 26, wherein said cancer is a Triple Negative Breast Cancer.
The method of any one of claims 23 to 27, wherein said detection is performed on paraffin-embedded tumor tissue samples, preferably by immunohistochemistry.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13734431.3A EP2867368B1 (en) | 2012-07-06 | 2013-07-08 | Simultaneous detection of cannibalism and senescence as prognostic marker for cancer |
US14/412,571 US9726661B2 (en) | 2012-07-06 | 2013-07-08 | Simultaneous detection of cannibalism and senescence as prognostic marker for cancer |
DK13734431.3T DK2867368T3 (en) | 2012-07-06 | 2013-07-08 | Simultaneous detection of cannibalism and senescence as prognostic marker for cancer |
US15/642,273 US10969380B2 (en) | 2012-07-06 | 2017-07-05 | Simultaneous detection of cannibalism and senescence as prognostic marker for cancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261668775P | 2012-07-06 | 2012-07-06 | |
US61/668,775 | 2012-07-06 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/412,571 A-371-Of-International US9726661B2 (en) | 2012-07-06 | 2013-07-08 | Simultaneous detection of cannibalism and senescence as prognostic marker for cancer |
US15/642,273 Division US10969380B2 (en) | 2012-07-06 | 2017-07-05 | Simultaneous detection of cannibalism and senescence as prognostic marker for cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014006227A1 true WO2014006227A1 (en) | 2014-01-09 |
Family
ID=48747585
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/064408 WO2014006227A1 (en) | 2012-07-06 | 2013-07-08 | Simultaneous detection of cannibalism and senescence as prognostic marker for cancer |
Country Status (4)
Country | Link |
---|---|
US (2) | US9726661B2 (en) |
EP (1) | EP2867368B1 (en) |
DK (1) | DK2867368T3 (en) |
WO (1) | WO2014006227A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018134443A1 (en) | 2017-01-23 | 2018-07-26 | Institut Gustave-Roussy | Enhancers of cellular cannibalism for use to sensitize tumors to radiation therapy |
WO2019145363A1 (en) | 2018-01-23 | 2019-08-01 | Institut Gustave-Roussy | Use of minaprine to reduce tumor growth |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10353516B2 (en) | 2015-04-24 | 2019-07-16 | Apple Inc. | Merged floating pixels in a touch screen |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000044895A1 (en) | 1999-01-30 | 2000-08-03 | Roland Kreutzer | Method and medicament for inhibiting the expression of a defined gene |
WO2002044321A2 (en) | 2000-12-01 | 2002-06-06 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference mediating small rna molecules |
US20050215497A1 (en) * | 2001-11-09 | 2005-09-29 | Annick Harel-Bellan | Inhibitor oligonucleotides and their use for specific repression of a gene |
WO2005100990A2 (en) * | 2004-04-13 | 2005-10-27 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2) |
WO2006078774A2 (en) * | 2005-01-19 | 2006-07-27 | The Trustees Of The University Of Pennsylvania | Regulation of autophagy and cell survival |
WO2009064590A2 (en) * | 2007-11-12 | 2009-05-22 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer |
WO2010083880A1 (en) * | 2009-01-21 | 2010-07-29 | Universita' Degli Studi Di Padova | Prognosis of breast cancer patients by monitoring the expression of two genes |
EP2272979A1 (en) * | 2009-06-30 | 2011-01-12 | Centre National de la Recherche Scientifique (CNRS) | Method for testing a subject thought to be predisposed to having cancer |
WO2011131472A1 (en) * | 2010-04-22 | 2011-10-27 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
WO2013009979A2 (en) * | 2011-07-13 | 2013-01-17 | Smith Holdings, Llc | Compositions and methods for suppressing gene expression of p53 and clusterin |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201120711D0 (en) * | 2011-12-01 | 2012-01-11 | Univ Erasmus Medical Ct | Method for classifying tumour cells |
US9890429B2 (en) * | 2012-02-29 | 2018-02-13 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the identification, assessment, prevention, and therapy of cancer |
-
2013
- 2013-07-08 DK DK13734431.3T patent/DK2867368T3/en active
- 2013-07-08 EP EP13734431.3A patent/EP2867368B1/en active Active
- 2013-07-08 US US14/412,571 patent/US9726661B2/en active Active
- 2013-07-08 WO PCT/EP2013/064408 patent/WO2014006227A1/en active Application Filing
-
2017
- 2017-07-05 US US15/642,273 patent/US10969380B2/en active Active
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000044895A1 (en) | 1999-01-30 | 2000-08-03 | Roland Kreutzer | Method and medicament for inhibiting the expression of a defined gene |
WO2002044321A2 (en) | 2000-12-01 | 2002-06-06 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Rna interference mediating small rna molecules |
US20050215497A1 (en) * | 2001-11-09 | 2005-09-29 | Annick Harel-Bellan | Inhibitor oligonucleotides and their use for specific repression of a gene |
WO2005100990A2 (en) * | 2004-04-13 | 2005-10-27 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2) |
WO2006078774A2 (en) * | 2005-01-19 | 2006-07-27 | The Trustees Of The University Of Pennsylvania | Regulation of autophagy and cell survival |
WO2009064590A2 (en) * | 2007-11-12 | 2009-05-22 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer |
WO2010083880A1 (en) * | 2009-01-21 | 2010-07-29 | Universita' Degli Studi Di Padova | Prognosis of breast cancer patients by monitoring the expression of two genes |
EP2272979A1 (en) * | 2009-06-30 | 2011-01-12 | Centre National de la Recherche Scientifique (CNRS) | Method for testing a subject thought to be predisposed to having cancer |
WO2011131472A1 (en) * | 2010-04-22 | 2011-10-27 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
WO2013009979A2 (en) * | 2011-07-13 | 2013-01-17 | Smith Holdings, Llc | Compositions and methods for suppressing gene expression of p53 and clusterin |
Non-Patent Citations (132)
Title |
---|
"Animal Cell Culture", 1986 |
"Current Protocols in Molecular Biology", 1994, JOHN WILEY & SONS, INC. |
"DNA Cloning: A Practical Approach", vol. I, II, 1985 |
"Immobilized Cells and Enzymes", 1986, IRL PRESS |
"Nucleic Acid Hybridization", 1984 |
"Oligonucleotide Synthesis", 1984 |
A. R.J. YOUNG ET AL: "Autophagy mediates the mitotic senescence transition", GENES & DEVELOPMENT, vol. 23, no. 7, 1 April 2009 (2009-04-01), pages 798 - 803, XP055080204, ISSN: 0890-9369, DOI: 10.1101/gad.519709 * |
ALESSANDRA S.K. TAMAJUSUKU ET AL: "Characterization of ATP-induced cell death in the GL261 mouse glioma", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 109, no. 5, 12 January 2010 (2010-01-12), pages 983 - 991, XP055091269, ISSN: 0730-2312, DOI: 10.1002/jcb.22478 * |
ARTHUR C R ET AL: "Autophagic cell death, polyploidy and senescence induced in breast tumor cells by the substituted pyrrole JG-03-14, a novel microtubule poison", BIOCHEMICAL PHARMACOLOGY, ELSEVIER, vol. 74, no. 7, 1 October 2007 (2007-10-01), pages 981 - 991, XP026863507, ISSN: 0006-2952, [retrieved on 20070823] * |
B. CHEVALLIER; V. MOSSERI; J. P. DAUCE; P. BASTIT; J. P. JULIEN; B. ASSELAIN: "A prognostic score in histological node negative breast cancer", BR J CANCER., vol. 61, no. 3, March 1990 (1990-03-01), pages 436 - 440 |
B. E. PERBAL, A PRACTICAL GUIDE TO MOLECULAR CLONING, 1984 |
BAGCHI S; LIAO Z; GONZALEZ FA; CHORNA NE; SEYE CI; WEISMAN GA; ERB L.: "The P2Y2 nucleotide receptor interacts with alphav integrins to activate Go and induce cell migration", J BIOL CHEM., vol. 280, no. 47, 25 November 2005 (2005-11-25), pages 39050 - 7 |
BENSAAD K; TSURUTA A; SELAK MA; VIDAL MN; NAKANO K; BARTRONS R; GOTTLIEB E; VOUSDEN KH.: "TIGAR, a p53 -inducible regulator of glycolysis and apoptosis", CELL, vol. 126, no. 1, 14 July 2006 (2006-07-14), pages 107 - 20 |
BENSAAD, CELL, 2006 |
BOURDON JC.: "p53 and its isoforms in cancer.", BR J CANCER., vol. 97, no. 3, 6 August 2007 (2007-08-06), pages 277 - 82 |
BOURDON, BRIT. J. CANCER, 2007 |
BURNSTOCK G.: "Purine and pyrimidine receptors", CELL MOL LIFE SCI., vol. 64, no. 12, June 2007 (2007-06-01), pages 1471 - 83, XP019511498, DOI: doi:10.1007/s00018-007-6497-0 |
BURNSTOCK, CELL MOL LIFE SCI., 2007 |
CANO CE ET AL., EMBO MOL MED., 2012 |
CANO CE; SANDI MJ; HAMIDI T; CALVO EL; TURRINI 0; BARTHOLIN L; LONCLE C; SECQ V; GARCIA S; LOMBERK G: "Homotypic cell cannibalism, a cell-death process regulated by the nuclear protein 1, opposes to metastasis in pancreatic cancer", EMBO MOL MED., vol. 4, no. 9, September 2012 (2012-09-01), pages 964 - 79 |
CANO ET AL., EMBO MOL MED., 2012 |
CANO ET AL., EMBO MOL. MED., 2012 |
CARTIER-MICHAUD A; MALO M; CHARRIERE-BERTRAND C; GADEA G; ANGUILLE C; SUPIRAMANIAM A; LESNE A; DELAPLACE F; HUTZLER G; ROUX P: "Matrix-bound PAI-1 supports cell blebbing via RhoA/ROCKl signaling", PLOS ONE, vol. 7, no. 2, 2012, pages E32204 |
CARTIER-MICHAUD, PLOS ONE, 2012 |
CHEN Y; CORRIDEN R; INOUE Y; YIP L; HASHIGUCHI N; ZINKERNAGEL A; NIZET V; INSEL PA; JUNGER WG.: "ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors", SCIENCE, vol. 314, no. 5806, 15 December 2006 (2006-12-15), pages 1792 - 5 |
COPPE, PLOS BIOL, 2008 |
DEMIDENKO, PNAS, 2010 |
DEMIDENKO, Z.N. ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 107, 2010, pages 9660 - 9664 |
DI X ET AL: "Apoptosis, autophagy, accelerated senescence and reactive oxygen in the response of human breast tumor cells to Adriamycin", BIOCHEMICAL PHARMACOLOGY, ELSEVIER, vol. 77, no. 7, 1 April 2009 (2009-04-01), pages 1139 - 1150, XP025967758, ISSN: 0006-2952, [retrieved on 20090106], DOI: 10.1016/J.BCP.2008.12.016 * |
EZGI TASDEMIR ET AL: "Regulation of autophagy by cytoplasmic p53", NATURE CELL BIOLOGY, vol. 10, no. 6, 1 June 2008 (2008-06-01), pages 676 - 687, XP055080665, ISSN: 1465-7392, DOI: 10.1038/ncb1730 * |
FARAAZ B. CHEKENI; MICHAEL R. ELLIOTT; JOANNA K. SANDILOS; SCOTT F. WALK; JASON M. KINCHEN; EDUARDO R. LAZAROWSKI; ALLISON J. ARMS: "Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis", NATURE, vol. 467, no. 7317, 14 October 2010 (2010-10-14), pages 863 - 867 |
FASANARO ET AL., PHARMACOL. THER, vol. 125, no. 1, 2010, pages 92 - 104 |
FASANARO ET AL., PHARMACOL. THER., 2010 |
FLOREY ET AL., NAT CELL BIOL., 2011 |
FLOREY; OVERHOLTZER, TRENDS CELL BIOL., 2012 |
FUJITA ET AL., NAT CELL BIOL, 2009 |
GADEA G; LAPASSET L; GAUTHIER-ROUVIERE C; ROUX P.: "Regulation of Cdc42-mediated morphological effects: a novel function for p53", EMBO J., vol. 21, no. 10, 15 May 2002 (2002-05-15), pages 2373 - 82, XP001093930, DOI: doi:10.1093/emboj/21.10.2373 |
GADEA, EMBO J., 2002 |
GADEA, J CELL BIOL., 2007 |
GILLES GADEA; MARION DE TOLEDO; CHRISTELLE ANGUILLE; PIERRE ROUX.: "Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices", J CELL BIOL., vol. 178, no. 1, 2 July 2007 (2007-07-02), pages 23 - 30 |
GONZALEZ-PASTOR ET AL., SCIENCE, 2003 |
GONZALEZ-PASTOR JE; HOBBS EC; LOSICK R.: "Cannibalism by sporulating bacteria", SCIENCE, vol. 301, no. 5632, 25 July 2003 (2003-07-25), pages 510 - 3 |
GOTTLIEB E; VOUSDEN KH.: "p53 regulation of metabolic pathways", COLD SPRING HARB PERSPECT BIOL., vol. 2, no. 4, April 2010 (2010-04-01), pages A001040 |
GOTTLIEB, COLD SPRING HARB PERSPECT BIOL, 2010 |
GRIMSLEY C; RAVICHANDRAN KS.: "Cues for apoptotic cell engulfment: eat-me, don't eat-me and come-get-me signals", TRENDS CELL BIOL., vol. 13, no. 12, December 2003 (2003-12-01), pages 648 - 56 |
GUIRAL ET AL., PNAS, 2005 |
GUIRAL S; MITCHELL TJ; MARTIN B; CLAVERYS JP.: "Competence-programmed predation of noncompetent cells in the human pathogen Streptococcus pneumoniae: genetic requirements", PROC NATL ACAD SCI USA., vol. 102, no. 24, 14 June 2005 (2005-06-14), pages 8710 - 5 |
GUO F; GAO Y; WANG L; ZHENG Y.: "p19Arf-p53 tumor suppressor pathway regulates cell motility by suppression of phosphoinositide 3-kinase and Racl GTPase activities", BIOL CHEM., vol. 278, no. 16, 18 April 2003 (2003-04-18), pages 14414 - 9 |
HöPFNER M. ET AL: "Growth inhibition and apoptosis induced by P2Y 2 receptors in human colorectal carcinoma cells: involvement of intracellular calcium and cyclic adenosine monophosphate", INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, vol. 16, no. 3, 1 June 2001 (2001-06-01), pages 154 - 166, XP055091618, ISSN: 0179-1958, DOI: 10.1007/s003840100302 * |
HA L; ICHIKAWA T; ANVER M; DICKINS R; LOWE S; SHARPLESS NE; KRIMPENFORT P; DEPINHO RA; BENNETT DC; SVIDERSKAYA EV: "ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence", PROC NATL ACAD SCI USA., vol. 104, no. 26, 26 June 2007 (2007-06-26), pages 10968 - 73 |
HA L; MERLINO G; SVIDERSKAYA EV.: "Melanomagenesis: overcoming the barrier of melanocyte senescence", CELL CYCLE., vol. 7, no. 13, 1 July 2008 (2008-07-01), pages 1944 - 8 |
HANAHAN D; WEINBERG RA.: "Hallmarks of cancer: the next generation", CELL, vol. 144, no. 5, 4 March 2011 (2011-03-04), pages 646 - 74, XP028185429, DOI: doi:10.1016/j.cell.2011.02.013 |
HANAHAN D; WEINBERG RA.: "The hallmarks of cancer", CELL, vol. 100, no. 1, 7 January 2000 (2000-01-07), pages 57 - 70, XP055447752 |
HANAHAN, CELL, 2000 |
HANAHAN, CELL, 2011 |
JÄNICKE RU; SOHN D; SCHULZE-OSTHOFF K.: "The dark side of a tumor suppressor: anti-apoptotic p53", CELL DEATH DIFFER, vol. 15, no. 6, June 2008 (2008-06-01), pages 959 - 76 |
JANICKE, CELL DEATH DIFFER, 2008 |
JEAN-PHILIPPE COPPE; CHRISTOPHER K PATIL; FRANCIS RODIER; YU SUN; DENISE P MUNOZ; JOSHUA GOLDSTEIN; PETER S NELSON; PIERRE-YVES DE: "Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor", PLOS BIOL., vol. 6, no. 12, December 2008 (2008-12-01), pages E301, XP055004326, DOI: doi:10.1371/journal.pbio.0060301 |
KAGHAD ET AL., CELL, 1997 |
KAGHAD M; BONNET H; YANG A; CREANCIER L; BISCAN JC; VALENT A; MINTY A; CHALON P; LELIAS JM; DUMONT X: "Monoallelically expressed gene related to p53 at lp36, a region frequently deleted in neuroblastoma and other human cancers", CELL, vol. 90, no. 4, 22 August 1997 (1997-08-22), pages 809 - 19, XP002934937, DOI: doi:10.1016/S0092-8674(00)80540-1 |
KAMB A; SHATTUCK-EIDENS D; EELES R; LIU Q; GRUIS NA; DING W; HUSSEY C; TRAN T; MIKI Y; WEAVER-FELDHAUS J ET AL.: "Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus", NAT GENET., vol. 8, no. L, September 1994 (1994-09-01), pages 23 - 6 |
KAMB ET AL., NAT GENET, 1994 |
KAORI FUJITA; ABDUL M. MONDAL; IZUMI HORIKAWA; GIANG H. NGUYEN; KENSUKE KUMAMOTO; JANE J. SOHN; ELISE D. BOWMAN; EWY A. MATHE; AAR: "p53 isoforms, A133p53 and p53p, are endogenous regulators of replicative cellular senescence.", NAT CELL BIOL, vol. 11, no. 9, September 2009 (2009-09-01), pages 1135 - 1142, XP055016287, DOI: doi:10.1038/ncb1928 |
KHOURY M.P.; BOURDON J.C., COLD SPRING HARB PERSPECT BIOL., 2010 |
KHOURY MP; BOURDON JC.: "The isoforms of the p53 protein", COLD SPRING HARB PERSPECT BIOL., vol. 2, no. 3, March 2010 (2010-03-01), pages A000927 |
KRAJCOVIC ET AL., NAT CELL BIOL, 2011 |
KRAJCOVIC ET AL., NAT CELL BIOL., 2011 |
KRAJCOVIC M; JOHNSON NB; SUN Q; NORMAND G; HOOVER N; YAO E; RICHARDSON AL; KING RW; CIBAS ES; SCHNITT SJ: "A non-genetic route to aneuploidy in human cancers.", NAT CELL BIOL., vol. 13, no. 3, March 2011 (2011-03-01), pages 324 - 30 |
KRAJCOVIC M; OVERHOLTZER M.: "Mechanisms of ploidy increase in human cancers: a new role for cell cannibalism", CANCER RES., vol. 72, no. 7, 1 April 2012 (2012-04-01), pages 1596 - 601 |
KRAJCOVIC; OVERHOLTZER, CANCER RES, 2012 |
KRAJCOVIC; OVERHOLTZER, CANCER RES., 2012 |
KUILMAN T; MICHALOGLOU C; MOOI WJ; PEEPER DS.: "The essence of senescence", GENES DEV., vol. 24, no. 22, 15 November 2010 (2010-11-15), pages 2463 - 79 |
LAURENCE ZITVOGEL ET AL: "Inflammasomes in carcinogenesis and anticancer immune responses", NATURE IMMUNOLOGY, vol. 13, no. 4, 1 April 2012 (2012-04-01), pages 343 - 351, XP055091179, ISSN: 1529-2908, DOI: 10.1038/ni.2224 * |
LEFORT K; MANDINOVA A; OSTANO P; KOLEV V; CALPINI V; KOLFSCHOTEN I; DEVGAN V; LIEB J; RAFFOUL W; HOHL D: "Notchl is a p53 target gene involved in human keratinocyte tumor suppression through negative regulation of ROCKl/2 and MRCKalphakinases", GENES DEV., vol. 21, no. 5, 1 March 2007 (2007-03-01), pages 562 - 77 |
LI C. ET AL., AAPSJ, 2009 |
LI C. ET AL., AAPSJ, vol. 11, no. 4, 2009, pages 747 - 757 |
LI W; BAKER NE.: "Engulfment is required for cell competition", CELL, vol. 129, no. 6, 15 June 2007 (2007-06-15), pages 1215 - 25 |
LI; BAKER, CELL, 2007 |
LIAO Z; SEYE CI; WEISMAN GA; ERB L.: "The P2Y2 nucleotide receptor requires interaction with alpha v integrins to access and activate G12", J CELL SCI., vol. 120, 1 May 2007 (2007-05-01), pages 1654 - 62 |
LIN HK; CHEN Z; WANG G; NARDELLA C; LEE SW; CHAN CH; YANG WL; WANG J; EGIA A; NAKAYAMA KI: "Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence", NATURE, vol. 464, no. 7287, 18 March 2010 (2010-03-18), pages 374 - 9, XP055275604, DOI: doi:10.1038/nature08815 |
LIU J; LIAO Z; CAMDEN J; GRIFFIN KD; GARRAD RC; SANTIAGO-PEREZ LI; GONZALEZ FA; SEYE CI; WEISMAN GA; ERB L.: "Src homology 3 binding sites in the P2Y2 nucleotide receptor interact with Src and regulate activities of Src, proline-rich tyrosine kinase 2, and growth factor receptors", J BIOL CHEM., vol. 279, no. 9, 27 February 2004 (2004-02-27), pages 8212 - 8 |
LOWE ET AL., NATURE, 2004 |
LOWE, S.W.; CEPERO, E.; EVAN, G.: "Intrinsic tumour suppression", NATURE, vol. 432, 2004, pages 307 - 315 |
LUKAS C; SAVIC V; BEKKER-JENSEN S; DOIL C; NEUMANN B; PEDERSEN RS; GROFTE M; CHAN KL; HICKSON ID; BARTEK J: "53BP1 nuclear bodies form around DNA lesions generated by mitotic transmission of chromosomes under replication stress", NAT CELL BIOL., vol. 13, no. 3, March 2011 (2011-03-01), pages 243 - 53 |
MARTINS ISABELLE ET AL: "Chemotherapy induces ATP release from tumor cells", CELL CYCLE, LANDES BIOSCIENCE, US, vol. 8, no. 22, 15 November 2009 (2009-11-15), pages 3723 - 3728, XP009128926, ISSN: 1538-4101 * |
MATHEW R ET AL: "Role of autophagy in cancer", NATURE REVIEWS. CANCER, NATUR PUBLISHING GROUP, LONDON, GB, vol. 7, no. 12, 1 December 2007 (2007-12-01), pages 961 - 967, XP002509609, ISSN: 1474-175X, DOI: 10.1038/NRC2254 * |
MATSUURA F; HIRANO K; IKEGAMI C; SANDOVAL JC; OKU H; YUASA-KAWASE M; TSUBAKIO- YAMAMOTO K; KOSEKI M; MASUDA D; TSUJII K: "Senescent phenotypes of skin fibroblasts from patients with Tangier disease", BIOCHEM BIOPHYS RES COMMUN, vol. 357, no. 2, 9 April 2007 (2007-04-09), pages 493 - 8, XP022055835, DOI: doi:10.1016/j.bbrc.2007.03.172 |
MICHAEL R. ELLIOTT ET AL: "Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance", NATURE, vol. 461, no. 7261, 10 September 2009 (2009-09-10), pages 282 - 286, XP055091346, ISSN: 0028-0836, DOI: 10.1038/nature08296 * |
OLIVER FLOREY; MICHAEL OVERHOLTZER.: "Autophagy proteins in macroendocytic engulfment", TRENDS CELL BIOL, vol. 22, no. 7, July 2012 (2012-07-01), pages 374 - 380, XP028498592, DOI: doi:10.1016/j.tcb.2012.04.005 |
OLIVER FLOREY; SUNG EUN KIM; CYNTHIA P. SANDOVAL; COLE M. HAYNES; MICHAEL OVERHOLTZER: "Autophagy machinery mediates macroendocytic processing and entotic cell death by targeting single membranes", NAT CELL BIOL., vol. 13, no. 11, 16 October 2011 (2011-10-16), pages 1335 - 1343 |
OVERHOLTZER ET AL., CELL, 2007 |
OVERHOLTZER ET AL., NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2008 |
OVERHOLTZER, M.; BRUGGE, J.S.: "The cell biology of cell-in-cell structures", NATURE REVIEWS MOLECULAR CELL BIOLOGY, vol. 9, 2008, pages 796 - 809, XP055320686, DOI: doi:10.1038/nrm2504 |
OVERHOLTZER, M.; MAILLEUX, A.A.; MOUNEIMNE, G.; NORMAND, G.; SCHNITT, S.J.; KING, R.W.; CIBAS, E.S.; BRUGGE, J.S.: "A nonapoptotic cell death process, entosis, that occurs by cell-in-cell invasion", CELL, vol. 131, 2007, pages 966 - 979 |
OVERHOLTZER; BRUGGE, NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2008 |
PAOLETTI ET AL., PNAS, 2012 |
PAOLETTI, A.; RAZA, S.Q.; VOISIN, L.; LAW, F.; PIPOLI DE FONSECA, J.; CAILLET, M.; KROEMER, G.; RIVETTI DI VAL CERVO, P.; LENA, A.: "p63-microRNA feedback in keratinocyte senescence", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 109, 2012, pages 1133 - 1138, XP055056063, DOI: doi:10.1073/pnas.1112257109 |
PARR CE. ET AL., PNAS, 1994, pages 1991 |
PARR CE. ET AL., PNAS, vol. 91, no. 8, 1994, pages 3275 - 9 |
RIVETTI DI VAL CERVO ET AL., PNAS, 2012 |
RIVETTI DI VAL CERVO ET AL., PROC NATL ACAD SCI U S A., vol. 109, no. 4, 24 January 2012 (2012-01-24), pages 1133 - 8 |
ROGER, L.; GADEA, G.; ROUX, P., CONTROL OF CELL MIGRATION: A TUMOUR SUPPRESSOR FUNCTION FOR P53 BIOLOGY OF THE CELL / UNDER THE AUSPICES OF THE EUROPEAN CELL BIOLOGY ORGANIZATION, vol. 98, 2006, pages 141 - 152 |
ROSS CORRIDEN; PAUL A.: "Insel.Basal Release of ATP: An Autocrine-Paracrine Mechanism for Cell Regulation", SCI SIGNAL., vol. 3, no. 104, 12 January 2010 (2010-01-12) |
SABLINA, A.A.; BUDANOV, A.V.; ILYINSKAYA, G.V.; AGAPOVA, L.S.; KRAVCHENKO, J.E.; CHUMAKOV, P.M.: "The antioxidant function of the p53 tumor suppressor", NATURE MEDICINE, vol. 11, 2005, pages 1306 - 1313, XP002410599, DOI: doi:10.1038/nm1320 |
SABLINA, A.A.; CHUMAKOV, P.M.; KOPNIN, B.P.: "Tumor suppressor p53 and its homologue p73alpha affect cell migration", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 278, 2003, pages 27362 - 27371 |
SABLINA, THE JOURNAL OF BIOLOGICAL CHEMISTRY, 2005 |
SAMBROOK; FITSCH; MANIATIS: "Molecular Cloning: A Laboratory Manual", 1989, COLD SPRING HARBOR LABORATORY PRESS |
SCHMITT ET AL., NATURE REVIEWS CANCER, 2003 |
SCHMITT, C.A.: "Senescence, apoptosis and therapy--cutting the lifelines of cancer", NATURE REVIEWS CANCER, vol. 3, 2003, pages 286 - 295 |
SEROR C. ET AL., THE JOURNAL OF EXPERIMENTAL MEDICINE, 2011 |
SEROR ET AL., THE JOURNAL OF EXPERIMENTAL MEDICINE, 2011 |
SEROR, C.; MELKI, M.T.; SUBRA, F.; RAZA, S.Q.; BRAS, M.; SAIDI, H.; NARDACCI, R.; VOISIN, L.; PAOLETTI, A.; LAW, F. ET AL.: "Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 I infection", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 208, 2011, pages 1823 - 1834 |
TASDEMIR, E.; MAIURI, M.C.; GALLUZZI, L.; VITALE, I.; DJAVAHERI-MERGNY, M.; D'AMELIO, M.; CRIOLLO, A.; TEODORO, J.G.; EVANS, S.K.;: "Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome", J MOL MED (BERL, vol. 85, 2007, pages 1175 - 1186, XP019553549, DOI: doi:10.1007/s00109-007-0221-2 |
TASDEMIR, J MOL MED, 2007 |
TOLSTONOG, G.V.; DEPPERT, W.: "Metabolic sensing by p53: keeping the balance between life and death", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 107, 2010, pages 13193 - 13194 |
TOLSTONOG, PNAS, 2010 |
VOGELSTEIN, B.; LANE, D.; LEVINE, A.J.: "Surfing the p53 network", NATURE, vol. 408, 2000, pages 307 - 310, XP008151714, DOI: doi:10.1038/35042675 |
VOGELSTEIN, NATURE, 2000 |
VOUSDEN, CELL, 2007 |
VOUSDEN, K.H.; LANE, D.P.: "p53 in health and disease", NATURE REVIEWS MOLECULAR CELL BIOLOGY, vol. 8, 2007, pages 275 - 283 |
VOUSDEN, K.H.; LU, X.: "Live or let die: the cell's response to p53", NATURE REVIEWS CANCER, vol. 2, 2002, pages 594 - 604 |
VOUSDEN, K.H.; PRIVES, C.: "Blinded by the Light: The Growing Complexity of p53", CELL, vol. 137, 2009, pages 413 - 431 |
VOUSDEN, NATURE REVIEWS CANCER, 2002 |
VOUSDEN, NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2009 |
WADDELL, D.R.; DUFFY, K.T.: "Breakdown of self/nonself recognition in cannibalistic strains of the predatory slime mold, Dictyostelium caveatum", THE JOURNAL OF CELL BIOLOGY, vol. 102, 1986, pages 298 - 305, XP009061116, DOI: doi:10.1083/jcb.102.1.298 |
WADDELL; DUFFY, THE JOURNAL OF CELL BIOLOGY, 1986 |
XIA, M.; LAND, H.: "Tumor suppressor p53 restricts Ras stimulation of RhoA and cancer cell motility", NATURE STRUCTURAL & MOLECULAR BIOLOGY, vol. 14, 2007, pages 215 - 223, XP002599921, DOI: doi:10.1038/NSMB1208 |
YANG A; KAGHAD M; WANG Y; GILLETT E; FLEMING MD; D6TSCH V; ANDREWS NC; CAPUT D; MCKEON F.: "p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities.", MOL CELL., vol. 2, no. 3, September 1998 (1998-09-01), pages 305 - 16, XP002101716, DOI: doi:10.1016/S1097-2765(00)80275-0 |
YANG ET AL., MOL. CELL, 1998 |
YONISH-ROUACH, E.; RESNITZKY, D.; LOTEM, J.; SACHS, L.; KIMCHI, A.; OREN, M.: "Wild- type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6", NATURE, vol. 352, 1991, pages 345 - 347 |
YONISH-ROUACH, NATURE, 1991 |
ZOYA N. DEMIDENKO; LIOUBOV G. KOROTCHKINA; ANDREI V. GUDKOV; MIKHAIL V. BLAGOSKLONNY.: "Paradoxical suppression of cellular senescence by p53", PROC NATL ACAD SCI U S A., vol. 107, no. 21, 25 May 2010 (2010-05-25), pages 9660 - 9664 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018134443A1 (en) | 2017-01-23 | 2018-07-26 | Institut Gustave-Roussy | Enhancers of cellular cannibalism for use to sensitize tumors to radiation therapy |
WO2019145363A1 (en) | 2018-01-23 | 2019-08-01 | Institut Gustave-Roussy | Use of minaprine to reduce tumor growth |
Also Published As
Publication number | Publication date |
---|---|
US9726661B2 (en) | 2017-08-08 |
US20150185202A1 (en) | 2015-07-02 |
EP2867368A1 (en) | 2015-05-06 |
US10969380B2 (en) | 2021-04-06 |
DK2867368T3 (en) | 2022-01-31 |
EP2867368B1 (en) | 2022-01-12 |
US20170363613A1 (en) | 2017-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wu et al. | Epithelial-mesenchymal transition directs stem cell polarity via regulation of mitofusin | |
Zhao et al. | Identification of transcription factor KLF8 as a downstream target of focal adhesion kinase in its regulation of cyclin D1 and cell cycle progression | |
Kinoshita et al. | Actin-related protein 2/3 complex subunit 5 (ARPC5) contributes to cell migration and invasion and is directly regulated by tumor-suppressive microRNA-133a in head and neck squamous cell carcinoma | |
Asangani et al. | Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer | |
Zhou et al. | Slit-Robo signaling induces malignant transformation through Hakai-mediated E-cadherin degradation during colorectal epithelial cell carcinogenesis | |
Xu et al. | FOXC1 contributes to microvascular invasion in primary hepatocellular carcinoma via regulating epithelial-mesenchymal transition | |
Grass et al. | CD147, CD44, and the epidermal growth factor receptor (EGFR) signaling pathway cooperate to regulate breast epithelial cell invasiveness | |
Xu et al. | MicroRNA-409-3p inhibits migration and invasion of bladder cancer cells via targeting c-Met | |
Taniuchi et al. | KIF20A-mediated RNA granule transport system promotes the invasiveness of pancreatic cancer cells | |
Xu et al. | TRIM29 overexpression is associated with poor prognosis and promotes tumor progression by activating Wnt/β-catenin pathway in cervical cancer | |
Xia et al. | Myosin phosphatase targeting subunit 1 affects cell migration by regulating myosin phosphorylation and actin assembly | |
Li et al. | MiR-141-3p functions as a tumor suppressor through directly targeting ZFR in non-small cell lung cancer | |
Liu et al. | Tumor suppressor miR-1 inhibits tumor growth and metastasis by simultaneously targeting multiple genes | |
Wang et al. | MicroRNA-575 targets BLID to promote growth and invasion of non-small cell lung cancer cells | |
Yi et al. | miR-202 inhibits the progression of human cervical cancer through inhibition of cyclin D1 | |
Liu et al. | Tiam1-regulated osteopontin in senescent fibroblasts contributes to the migration and invasion of associated epithelial cells | |
Choi et al. | miR-93-5p suppresses cellular senescence by directly targeting Bcl-w and p21 | |
Deng et al. | MiR-429 suppresses the progression and metastasis of osteosarcoma by targeting ZEB1 | |
US10969380B2 (en) | Simultaneous detection of cannibalism and senescence as prognostic marker for cancer | |
Zuo et al. | The type 1 transmembrane glycoprotein B7‐H3 interacts with the glycolytic enzyme ENO 1 to promote malignancy and glycolysis in HeLa cells | |
Li et al. | The role of transcriptional coactivator TAZ in gliomas | |
Wang et al. | Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity | |
Huang et al. | LINC02381 aggravates breast cancer through the miR‐1271‐5p/FN1 axis to activate PI3K/AKT pathway | |
Zhang et al. | Protease activated receptor 2 mediates tryptase-induced cell migration through MYO10 in colorectal cancer | |
Zhang et al. | USP39 facilitates breast cancer cell proliferation through stabilization of FOXM1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13734431 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14412571 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013734431 Country of ref document: EP |